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Abstract 
Bone Regulating Hormones and Nutrients in the Characterization of the Metabolically 
Healthy Obese Phenotype: A Cross-Sectional Pilot Study 
Kendra Vos Becker 
Deeptha Sukumar, Ph.D. 
 
 
 
 
The term metabolically healthy obese (MHO) phenotype has been used to describe those 
who present with a benign metabolic profile despite excess adiposity.  The MHO 
phenotype is commonly defined as completely free of metabolic abnormalities or less 
than three components of metabolic syndrome.  Bone regulating hormones, such as 
parathyroid hormone (PTH), 25-hydroxyvitamin D (25OHD), estrogen, and more 
recently osteocalcin, have been shown to play an important role in overall energy 
metabolism.  Bone regulating nutrients such as calcium, vitamin D and magnesium (Mg) 
are also important regulators of energy metabolism.  The goal of this study is to 
determine whether bone regulating hormones and nutrients can help characterize the 
MHO phenotype.  We hypothesized that adequate Mg status, higher serum 25OHD and 
lower serum PTH concentrations would protect against metabolic abnormalities in 
overweight and obese individuals.  The present case control design included 27 adult 
participants who were considered overweight or obese, evidenced by a body mass index 
(BMI) of 25-40 kg/m2.  Measurements were obtained of the participants’ Mg status and 
serum 25OHD, serum PTH levels, body fat percentage, trunk fat percentage, body fat 
mass, blood pressure, glycemic indices, lipid profile, and pro-inflammatory cytokines in 
order to determine what metabolic factors that set the metabolically healthy apart from 
		
xii	
the rest of the overweight and obese populations.  Age and weight matched participants 
were then classified as MHO (n=13) or metabolically unhealthy obese (MUO) (n=14) 
using percent trunk fat based on the sample median (<19.2% for MHO and ≥19.2% for 
MUO).  The collected data was analyzed using descriptive statistical methods 
appropriate for cross-study comparisons.  The mean age of the MHO (29.99 ± 8.57 yr) 
and MUO (34.26 ± 9.38 yr) did not differ significantly. In the MHO group, serum insulin 
concentrations were significantly lower (p < 0.04) than the MUO group.  Systolic BP did 
not differ between groups yet diastolic BP tended (p < 0.07) to be lower in the MHO 
group.  Triglyceride and c-reactive protein (CRP) levels did not differ between groups. 
Magnesium intake tended to be higher in the MHO group (270.39 ± 181.71 mg/day) than 
the MUO group (195.38 ± 88.94 mg/day). Serum 25OHD concentrations did not differ 
between groups, however there was a significant difference (p < 0.04) in ionized Mg 
concentrations in the MHO group (0.565 ± 0.41 mmol/L) than in the MUO group (0.525 ± 
0.050 mmol/L).  Furthermore, serum PTH levels were significantly higher (p < 0.02) in 
the MUO group (61.77 ± 25.92 pg/mL) than the MHO group (40.19 ± 11.49 pg/mL).  
Serum osteocalcin concentrations and serum c-telopeptide collagen (CTx) concentrations 
tended to be higher in the MHO compared to the MUO group. These findings suggest 
that the bone regulating hormones can characterize the metabolically healthy obese 
phenotype.  Future studies should consider examining these bone regulating hormones 
and nutrients in characterizing the MHO phenotype.  Importantly, alterations in these 
hormones and nutrients can be a potential target for intervention for prevention of 
metabolic abnormalities. 
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STUDY BACKGROUND 
 
 
 
The metabolically healthy obese (MHO) phenotype describes a subgroup existing within 
the overweight-obese population who are largely free of the metabolic abnormalities 
expected with excess adiposity.  The protective factors benefiting those considered to be 
MHO have not been established, but are thought to be multifaceted.  Bone regulating 
hormones and nutrients play a role in energy metabolism, and aberrations in some, such 
as vitamin D, parathyroid hormone (PTH), and magnesium, have been linked to 
metabolic abnormalities.  In this study, we are exploring the possibility of bone 
regulating hormones and nutrients playing a protective role in the MHO phenotype. 
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AIMS AND HYPOTHESES 
 
 
1. To determine whether differences in bone regulating hormones characterize the 
phenotype of metabolically healthy overweight-obese individuals compared to 
metabolically unhealthy overweight-obese individuals 
Hypothesis 1: We hypothesize that metabolically healthy overweight-obese individuals will have 
higher serum concentrations of 25-hydroxyvitamin D compared to metabolically unhealthy 
overweight-obese individuals  
Hypothesis 2: We hypothesize that metabolically healthy overweight-obese individuals will have 
lower serum concentrations of parathyroid hormone compared metabolically unhealthy 
overweight-obese individuals 
2. To determine whether differences in bone regulating nutrients characterize the 
phenotype of metabolically healthy overweight-obese individuals compared to 
metabolically unhealthy overweight-obese individuals 
Hypothesis 1: We hypothesize that metabolically healthy overweight-obese individuals will have 
higher dietary intakes of magnesium compared to metabolically unhealthy overweight-obese 
individuals  
Hypothesis 2: We hypothesize that metabolically healthy overweight-obese individuals will have 
higher dietary intakes of calcium compared to metabolically unhealthy overweight-obese 
individuals  
		
xv	
3. To determine whether a relationship exists between magnesium status, bone 
regulating hormones, and adiposity. 
Hypothesis 1: We hypothesize that there will be a negative correlation between serum ionized 
magnesium concentrations and percent body fat. 
Hypothesis 2: We hypothesize that there will be a positive correlation between serum parathyroid 
hormone and fat mass. 
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CHAPTER 1. BACKGROUND 
 
1.1 Introduction 
Adults with a body mass index (BMI) categorized as overweight (25.0-29.9 
kg/m2) or obese (≥30.0 kg/m2) are considered to be at higher risk of developing a 
multitude of health complications.1 Extensive research has demonstrated how those with 
excessive adiposity commonly present with a cluster of distinct comorbidities, including 
hypertension (HTN), insulin resistance, and dyslipidemia.1-3  These metabolic 
abnormalities often double the risk of developing cardiovascular disease (CVD) and 
amplify the risk for type 2 diabetes mellitus (T2DM) by five-fold.4,5 
 
1.1.1 Metabolic Abnormalities in Obesity 
The comingling of metabolic abnormalities is clinically defined as the metabolic 
syndrome (MetS), a condition that is steadily becoming more prevalent in the United 
States and across the world.2 A diagnosis of MetS is made with the presence of 3 or more 
symptoms out of a set of 5 parameters: a larger waist circumference (WC), elevated 
blood pressure (BP), high fasting blood glucose (FBG), high triglycerides and low high-
density lipoprotein cholesterol (HDL-C).2,4  The differing criteria for MetS from the 
International Diabetes Federation (IDF) and the American Heart Association/National 
Heart, Lung, and Blood Institute (AHA/NHLBI) have been harmonized into a 
standardized diagnostic protocol (See table 1).5  High BP is defined as elevation in either 
systolic BP (SBP) or diastolic BP (DBP).  Abdominal obesity plays a role in the 
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development of insulin resistance and systemic inflammation associated with risk 
factors of CVD, which is why WC is a criterion for the MetS.5  Depending on hereditary 
and geographical factors, the cut off point defining abdominal obesity can vary for 
different populations.  Increased risk for CVD is associated with lower WC values of ≥85 
cm for men and ≥80 cm for women in certain populations, such as in China and India 
(Alberti et al., 2009).5 In the United States, the categorical cut points for WC are ≥102 cm 
in men and ≥88 cm in women, much higher than Asian populations and slightly higher 
than Europe and Canada (≥94 cm in men and ≥80 cm in women).  The discordance in 
WC values used for MetS diagnosis account for increased risk for certain populations, 
while also reducing cases of MetS in countries utilizing higher cut points.5  
 
 
 
Table 1: Clinical Criteria for Diagnosis of Metabolic Syndrome in the USA 
 
Measure 
 
Women 
 
Men 
Larger WC (cm)* ≥88 ≥102 
Elevated BP (mmHg) SBP≥130 and/or DBP≥85 SBP ≥130 and/or DBP ≥85 
High FBG (mg/dL) ≥100 ≥100 
High Serum TGL (mg/dL) ≥150 ≥150 
Reduced HDL-C (mg/dL) >50 >40 
Abbreviations: WC, waist circumference; BP, blood pressure; SBP, systolic blood pressure; DBP, diastolic blood pressure; 
FBG, fasting blood glucose; TGL, triglyceride; HDL-C, high density lipoprotein-cholesterol. 
*Varies according to country and population specifics5 
 
 
With multiple components of MetS comes increased risk of CVD, T2DM, and 
osteoporosis.1,6  Ample evidence supports the interconnectedness of the seemingly 
isolated metabolic disturbances of increased abdominal fat, lipid metabolism, glucose 
uptake, and elevated BP.1,3,6  For example, increased adipose tissue promotes insulin 
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resistance, or hyperinsulinemia, which is strongly associated with dyslipidemia, HTN, 
and the development of atherosclerosis.1  Imbalances in one metabolic pathway 
interrupt other physiological processes, leading to a vicious self-generating cycle of 
disrupted enzyme regulation, metabolic dysfunction, and disease development.4,7,8   
Systemic inflammation arises with metabolic abnormalities and is an important 
contributing factor to the progression of chronic diseases associated with obesity.2,8  The 
measurement of plasma C-reactive protein (CRP), a pro-inflammatory biomarker, is one 
way to gauge the severity of innate immune response, which can independently have a 
deleterious effect on health.2,8  Other specific factors linking these metabolic 
abnormalities together are being investigated, some evidence pointing to the nonskeletal 
influence of bone-regulating hormones, such as vitamin D and parathyroid hormone 
(PTH), and certain nutrients one being magnesium (Mg).4,9     
 
1.2 Metabolically Healthy Obese Phenotype 
Although obesity is frequently associated with metabolic abnormalities and 
viewed as a homogenous condition, an important subgroup within the overweight and 
obese populations who lack the expected comorbidities despite their predictive body 
composition is now being recognized.3,4,7,10  The term metabolically healthy obese (MHO) 
phenotype originated to describe the phenomenon of obesity with a benign metabolic 
status, although individuals categorized as overweight (BMI 25-29.9 kg/m2) are often 
included in the subgroup.4,7,10  To be considered MHO, an individual is largely free of the 
common risk factors of CVD despite a BMI (kg/m2) classification of overweight or 
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obese.11  They have normal BP, higher levels of insulin sensitivity, a favorable lipid 
profile, and lower levels of pro-inflammatory cytokines, limiting the major contributors 
of chronic disease pathogenesis.  In an effort to characterize the MHO phenotype and 
map the health benefits experienced by the subgroup, numerous studies have 
investigated possible protective factors and how risk of disease compares to 
metabolically unhealthy obese (MUO) individuals in all weight categories.  While there 
is no standard definition of MHO, most sample populations are categorized according to 
the absence of metabolic syndrome or the complete absence of all components of MetS 
(See table 2).     
 
1.2.1 Benefits of the metabolically healthy obese phenotype 
In a 2006 community-based, longitudinal study examining 2902 adults without 
T2DM or CVD (mean age 53 years), Meigs et al. reported that adiposity alone without 
metabolic abnormalities did not increase the risk of CVD and was a weak determinant in 
the incidence of T2DM over 11 years.12  Risk of CVD in MHO individuals remained 
comparable to their metabolically healthy nonobese counterparts after 7 years in an 
observational study conducted by Hamer et al., while their WC and BMI was 
consistently lower than the metabolically unhealthy obese (MUO) group.11  When 
Ogorodnikova et al. pooled data from the Atherosclerosis Risk in Communities (ARIC) 
and Cardiovascular Health Studies (CHS), the MHO phenotype was not associated with 
a significantly increased incidence of CVD (8.7%, 7.2%, and 10.3%) according to three 
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different definitions of metabolically benign when compared to the corresponding low-
risk normal weight group (7.9%) in an 11.8-year follow-up.13   
After analyzign data drawn from the Whitehill II study, a London-based 
prospective cohort of 7122 men and women, Hinnouho et al. reported significantly 
lower BP, FBG, triglyceride and low-density lipoprotein cholesterol (LDL-C) and higher 
HDL-C in the MHO group compared to the MUO group.14,15  These results led to the 
conclusion that the MHO phenotype awarded individuals a decreased risk for CVD 
development, while still being elevated in both obesity phenotypes.  They also reported 
overweight and obese individuals to be at higher risk for T2DM compared to normal 
weight controls.  In a cross-sectional study of 88 nondiabetic overweight and obese 
postmenopausal women, Karelis et al. reported the MHO group to have 49% less 
visceral adipose tissue than the MUO group, and their CRP levels were 92.7% lower.10  
The reduced CRP in MHO individuals appeared to be a marker of less visceral fat 
content.   Finally, Moore et al. concluded MUO to be twice as likely to develop obesity-
related cancers than normal weight participants, while MHO had only a 47% increased 
risk of cancer compared to normal weight participants.16  In men, higher WC (>94 cm) 
was associated with 4-fold increased risk of obesity-associated cancer than those in 
lower WC category (< 84 cm).16 
Strong consistencies in study results outweigh conflicting evidence, offering new 
insight into the level of protection against disease.  The MHO phenotype seems to be 
protective against systemic inflammation evidenced by normal levels of CRP and 
smaller WC, both indicators of visceral adiposity.10,16  In addition, higher insulin 
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sensitivity is consistently found in MHO individuals, thus lowering risk for developing 
T2DM.  When analyzed together, previous studies suggest the MHO phenotype has a 
risk factor for CVD between that of normal weight healthy and MUO individuals.  The 
MHO individual is still at increased risk for CVD and all-cause mortality compared to 
healthy lean counterparts, but will develop chronic disease more slowly than MUO.10  
The goal of characterizing the MHO phenotype is not to postpone weight loss, but rather 
to determine protective mechanisms against metabolic abnormalities until weight loss 
can be achieved.10,16 
 
1.2.2 Prevalence of the metabolically healthy obese phenotype 
The prevalence of the MHO phenotype decreases within each escalating BMI 
category.14  For instance, there is a substantial drop in the proportion of MHO in normal 
weight compared to overweight populations, illustrating an increased pattern of 
metabolic dysfunction and the need to include the overweight BMI category in the 
search for protective factors.14  In addition to proportional changes occurring across BMI 
classifications, prevalence also varies according to age, sex, and definition used.  Women 
are more likely to have the MHO phenotype than men, and as to be expected, the 
prevalence is much higher in younger populations.  To be discussed, the definition 
employed can cause variation in prevalence, ranging from 6.0% to 38.4%.  In the United 
States, 30-35% of the obese population is estimated to be metabolically healthy, while 
prevalence of MHO was estimated at 8.7% in a sample of individuals with abdominal 
obesity verifying the implications of increased visceral fat.   
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Without a globally standardized definition, investigators have allocated subjects 
to their MHO study group using different combinations of MetS components and other 
risk factors of CVD (See table 2).  The prevalence of MHO in a sample population is 
lower or higher depending on whether the definition used was a complete absence of 
MetS components or an absence of a clinical diagnosis of MetS, respectively.  
Ogorodnikova et al. classified obese participants (BMI ≥30) as metabolically benign 
according to three differing definitions, placing those who fit the criteria in the MHO 
group corresponding to each definition.13  Out of a sample size of 6,121 obese 
individuals, prevalence of the MHO phenotype was 27.0%, 18.1%, and 20.4%, varying by 
definition.13 
 
 
Table 2: Varying Definitions of the Metabolically Healthy Obese Phenotype3,4,7,11,12,17,18 
        
Variable Kanagasabai 
et al. (2015) 
Guerrero-
Romano et 
al. (2013) 
Hwang et 
al. (2012) 
Hamer et 
al. (2012) 
Wildman 
et al. (2008) 
Aguilar-
Salinas et 
al. (2008) 
Meigs et al. 
(2006) 
BMI 
(kg/m2) 
≥30  ≥25  Overweight 
or obese 
≥25 ≥30 ≥30 ≥30 
WC (cm) ≥102cm (M) 
≥88cm (W) 
 ≥90cm (M) 
≥80cm (W) 
≥102cm(M) 
≥88cm (W) 
  ≥102cm(M) 
≥88cm (W) 
BP (mmHg) SBP ≥130 or 
DBP ≥85 
Absence of 
HTN 
SBP≥130 or 
DBP≥85 
SBP≥130 or 
DBP≥85 
SBP≥130 or 
DBP≥85 
SBP<140 + 
DBP<90 
SBP≥130 or 
DBP≥85 
FBG 
(mg/dL) 
≥100 ≥100  ≥100  ≥100 ≥100 <126 ≥100 
TGL 
(mg/dL) 
≥150 ≥150 ≥150  ≥150  ≥150 
HDL-C 
(mg/dL) 
<40 (M) 
<50 (W) 
 <40 (M) 
<50 (W) 
<40 (M) 
<50 (W) 
<40 (M) 
<50 (W) 
≥39 <40 (M) 
<50 (W) 
Other  ≥3 HOMA-
IR 
>6.5% 
HbA1c 
CRP≥0.3 
mg/dL 
CRP ≥90th 
percentile 
  
Criteria for 
MHO 
≤2 of above 
 
None None  None < 2 of 
above  
All < 3 of 
above  
Abbreviations: BMI, body mass index; WC, waist circumference; BP, blood pressure; SBP, systolic blood pressure; DBP, 
diastolic blood pressure; FBG, fasting blood glucose; TGL, triglyceride; HDL-C, high density lipoprotein-cholesterol; 
MHO, metabolically healthy obese. 
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There is growing scientific and medical interest in the MHO subgroup, as 
ramifications of the health-preserving characteristics could individualize our current 
knowledge of chronic disease development.  The exact attributes of the novel phenotype 
have yet to be defined and possible protective factors are still being investigated.3,4,7  A 
small assemblage of studies have examined the influence of bone regulating hormones 
and nutrients in the development of metabolic abnormalities coinciding with excess 
adiposity.  Results have shown promise; suggesting a relationship exists, and correction 
of imbalances in these hormones and nutrients could offer a route of protection against 
metabolic alterations. 
 
1.3 Bone and Adipose Tissue as Endocrine Organs 
Previously thought to be static tissues, the recent acknowledgement of bone and 
adipose tissue as endocrine organs has been a prominent revelation in human 
health.3,19,20  New insights reveal the human skeleton as offering much more than 
structural support, and adipose tissue acting as more than an insulator and energy 
depot.19  Normal functioning of both tissues relies on endocrine factors from other 
organs while other organ systems are affected by the functions of bone and fat.19  One 
link between bone health and metabolism lies in the metamorphic tendencies of stromal 
cells, which differentiate to osteoblasts or adipocytes depending on physiologic 
conditions.21  Certain bone regulating hormones and nutrients control the direction of 
stromal cell maturation, offering one example of coalescing influence.  Further 
emphasizing the interconnectedness of the tissue types, the pleiotropic actions of bone 
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regulating hormones and nutrients in bone physiology and energy metabolism appear 
to be synchronized.19   
Coordinated regulation is exhibited in calcium homeostasis, where the amount of 
calcium absorbed, stored in bone, and maintained in extra- and intra-cellular 
compartments is tightly controlled through feedback mechanisms between bone 
regulating hormones and nutrients. Imbalances in energy metabolism will cause 
complications to arise in the skeletal system, much like the common coexistence of 
T2DM and osteoporosis.19 Emerging evidence has confirmed the dynamic hormonal 
activities of vitamin D, parathyroid hormone (PTH), estrogen, and osteocalcin, as well as 
the role of protein, calcium, and magnesium (Mg), in metabolic processes and bone 
integrity.22,23,24    
 
1.4 Influence of Bone Regulating Hormones and Nutrients on Bone Health 
Skeletal remodeling is a continuous transaction of mineral deposition by 
osteoclasts and resorption by osteoblasts, with exchanges corresponding to blood levels 
of minerals.19  Under optimal conditions, there is a balance between the opposing 
activities of osteocytes and bone mineral density (BMD) is conserved.   
 
1.4.1 Bone Regulating Hormones 
Vitamin D is imperative for calcium and phosphate homeostasis, both critical 
minerals in bone structure, growth, and maintenance, as well as cellular metabolism.  
Adequate concentrations of circulating calcium and phosphorus are required to meet the 
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needs of tissues throughout the body.  In its active form, vitamin D works on a 
transcriptional level, regulating the expression of proteins in direct control of calcium 
and phosphorus intestinal absorption and blood concentrations.1  As a molecular 
regulator, vitamin D also modulates bone metabolism by suppressing the proliferation 
of osteoclasts, and stimulating stromal cell differentiation to osteoblasts.21  Increased 
bone loss and risk of fracture are associated with compromised vitamin D status.21,24   
The parathyroid gland produces parathyroid hormone (PTH), which couples 
with vitamin D in the homeostatic control of calcium and phosphorus.1  These two bone 
regulating hormones function in a negative feedback loop.  When serum calcium levels 
are low, PTH secretion increases to stimulate the final activation of vitamin D in the 
kidneys to its hormonal form for assistance in calcium intestinal absorption.25  As 
calcium concentrations return to normal, the release of PTH is suppressed by the influx 
of calcium and activated vitamin D.  The initial rise in PTH will provoke osteoblastic 
activity and bone deposition, utilizing the newly available calcium to increase bone 
mineral density (BMD).24  However, if vitamin D levels remain low, PTH becomes 
chronically elevated, thereby promoting osteoclastic activity to compensate for the 
impaired calcium absorption.24  A balance between levels of vitamin D and PTH are 
necessary to prevent the release of bone minerals into circulation from surpassing 
deposition.25  Both compounds are integral to calcium metabolism.9       
Like vitamin D and PTH, estrogen, and osteocalcin also connects the divide 
between bone and metabolism.  Declining estrogen production in the ovaries is 
recognized as a major cause of postmenopausal bone loss.26  In 1988, Eriksen et al. found 
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estrogen receptors displayed on cultured human osteoblast-like cells, confirming a direct 
affect on bone health.26,27  Bone resorption increases with marginal downturns in 
estrogen production.21  As an endocrine organ and producer of sex steroids, adipose 
tissue contributes to total estrogen levels.  This finding is supported by the results of 
numerous weight loss studies, which report a correlation between BMD loss and 
reduction in circulating estradiol as body fat decreases.21   
Previous studies also report an increased risk of fracture when a combination of 
low estrogen and low vitamin D are present, and amelioration of bone loss with 
hormone replacement therapy, thus helping to prevent menopause-related 
osteoporosis.21,28  Osteocalcin (OC) is derived from osteoblasts, which synthesize and 
secrete the protein into the bone extracellular matrix.9,19  Although originating in bone, 
current evidence suggests OC targets distant tissues, adding to the mounting evidence 
implicating the skeletal system as endocrine organ.  Experimental results indicate the 
influence of OC on glucose homeostasis, possibly signaling for insulin secretion of 
pancreatic β-cells and stimulating receptors for glucose uptake in adipose tissue.9 
 
1.4.2 Bone Regulating Nutrients 
While known to be important in energy metabolism, specific nutrients also 
playing a role in bone health.24  Results from multiple studies have demonstrated how 
higher protein intakes (approximately 24% of total daily calories) attenuate BMD 
depletion during weight loss, caloric restriction, and menopause, as well as promotes 
healing after fractures.21,24  The possible mechanistic influences on bone include 
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increased calcium absorption and the maintenance of insulin-like growth factor (IGF-1), 
subsequently inducing osteoblast differentiation and matrix crystallization.21,22  
Adequate intake of calcium intrinsically preserves bone health as an essential element of 
structure.  In addition, calcium influences BMD indirectly through the negative feedback 
loop with PTH, thus inhibiting disproportional bone resorption.1   
Recently, the role of Mg in bone health and metabolism is receiving attention, yet 
there is still much to elucidate.1  To date, there have been no randomized, double-blind, 
placebo controlled trials, considered the gold standard of research, testing the 
relationship between Mg and bone, although data from epidemiological studies 
confirms a positive correlation between dietary intake and bone health.1  Investigators 
using animal models have described an increase in osteoclastic activity and reduction in 
bone integrity with dietary restriction of Mg.1  The potential mechanistic influences of 
Mg on bone include its role in osteoblastic activity, crystal formation, as well as the 
promotion of osteoclastic activity by the elevation of proinflammatory cytokines 
common with Mg deficiency.1,29 
 
1.5 Functions of Bone Regulating Hormones and Nutrients 
1.5.1 Vitamin D 
With functions resembling that of a hormone, the categorization of Vitamin D, or 
cholcalciferol, as a vitamin does not accurately describe the biological role this molecule 
plays.  Analogous to a hormone, it is produced endogenously when skin is exposed to 
sunlight.1  Dietary sources of vitamin D are limited to fatty fish, fish oil, organ meats, 
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egg yolks, and certain mushroom species, yet these foods become critical depending on 
a host of compromising factors.1  Skin pigmentation, season, geographical latitude, angle 
of the sun, presence of sunscreen, and amount of skin exposed can all impact an 
individual’s vitamin D status.1,25  The cutaneous synthesis of vitamin D3 occurs when 
ultraviolet (UV) B radiation (290-315 nm) stimulate the isomerization of 7-
dehydrocholesterol in epidermal and dermal layers.25  Once conversion occurs, the 
hormone is transported to the liver by vitamin D binding protein (VDBP).  The pathway 
of activation begins with a hepatic hydroxylation of vitamin D to 25-hydroxyvitamin D 
(25OHD) by 25-hydroxylase.  The second hydroxylation occurs in the kidney where the 
renal enzyme, 1α-hydroxylase, converts 25OHD to 1α,25-dihydroxyvitamin D [1α,25-
(OH)2D], the metabolically active and hormonal form.4  The enzyme 24-hydroxylase is 
stimulated by 1α,25-(OH)2D, and is responsible for the degradation of both 25OHD and 
1α,25-(OH)2D to inactive metabolites.30  The endocrine functions of 1α,25-(OH)2D, or 
calcitriol, are categorized by its actions in calcium homeostasis and its regulatory actions 
in many physiological sites, such as bone marrow, the immune system, the intestine, 
skeletal muscle, and adipose tissue.1  Like a hormone, vitamin D interacts with nuclear 
receptors to enhance or inhibit gene expression, including the transcription of proteins 
involved in energy metabolism and calcium absorption.   
 
1.5.2 Parathyroid Hormone 
The primary function of PTH is maintaining calcium homeostasis by targeting 
the proximal tubules of the kidneys for calcium reabsorption and vitamin D activation, 
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as well as bone resorption of minerals.  The renal enzyme 1α-hydroxylase is PTH-
activated to stimulate the conversion of 25OHD to 1α,25-(OH)2D, which is then 
transported to the intestine via VDBP and binds to the vitamin D receptor (VDR) on the 
cell surface of enterocytes.1  Once liganded, the VDR complex enters the nucleus where 
it interacts with transcriptional elements for vitamin D-dependent genes.  In the case of 
calcium absorption, an up-regulation of calcium pumps and channel proteins will occur, 
moving calcium from the intestinal lumen to the epithelium and into circulation where it 
becomes available for utilization in many biological processes.1 
 
1.5.3 Magnesium 
As an intracellular divalent cation, ionized Mg (iMg2+) functions as a major 
cofactor for enzymes involved in the physiological pathways of lipid and carbohydrate 
metabolism.6,31,32  For instance, the Mg adenosine triphosphate (ATP) complex provides 
energy for phosphorylation reactions catalyzed by glycolytic enzymes and in the 
tricarboxylic acid cycle (TCA), thus playing an integral role in energy metabolism.1   
Other enzymes, such as protein kinases and ribonucleic acid (RNA) and 
Deoxyribonucleic acid (DNA) polymerases, require the binding of Mg2+ for activation. 
Intracellular signaling cascades of the cyclic adensoine monophosphate (cAMP) 
and phospholipase C second-messenger system involve Mg; therefore, this mineral is 
essential for endocrine response, signaling pathways, and DNA synthesis, integrity, and 
transcription.1,29,33  Ionized Mg is also involved in cardiac function, nerve transmission, 
and vasodilation by changing electrochemical gradients of the cellular membrane ion 
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channels with calcium and potassium.2,33,34  There is an influx of iMg2+ when intracellular 
calcium is low and free extracellular iMg2+ can block the entrance of calcium into the cell, 
both actions being consequential to energy metabolism and weight balance.34-36  There is 
evidence of Mg status being inversely associated with a host of pathological conditions, 
such as those involved in MetS.34  With many functions, Mg is a critical component in 
hundreds of biological processes.  Its actions in the second-messenger systems of cAMP 
and phospholipase C, and its role as an intracellular calcium antagonist, are particularly 
relevant to its metabolic influence and relationship with vitamin D and PTH.1,2,37 
 
1.5.4 Calcium Homeostasis 
The reciprocal actions among vitamin D, PTH, and Mg are complex, involving 
regulatory loops between each pair for the predominant purpose of calcium 
homeostasis.31,38,39  The multiple steps to activation of vitamin D to 1,25(OH)2D and the 
regulation of PTH secretion are Mg-dependent, partially explaining the synergism of 
these three biochemical entities.6  The enzymes responsible for hepatic 25-hydroxylation, 
renal 1α-hydroxylation, and calcitriol degredation require Mg as a cofactor, while 
vitamin D binding to its transport protein also relies on Mg.35  Results from in vitro 
studies suggest Mg as a regulator of 1α-hydroxylase and 24-hydroxylase activity, and 
VDBP expression, while increased Mg intakes correlate with increased serum 25OHD, 
the best biochemical marker of vitamin D status in human studies.35  
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1.5.5 Interactions between Bone Regulating Hormones and Nutrients   
Calcium adsorption in the intestinal mucosa is dependent on the availability of 
1,25(OH)2D3.8  If blood calcium concentrations are low, the parathyroid gland responds 
to falling levels by secreting excess PTH for calcium resorption from bone and 25OHD 
hydroxylation in the proximal tubule of the kidney.1,20  Levels of PTH return to normal 
once calcium  homeostasis has been attained.  The influence of Mg on bone-regulating, 
or calciotropic, hormones is further evidenced by the suppression of PTH production as 
a result of Mg repletion in animal studies.31  Deng et al. analyzed data sets from the 2001 
and 2006 National Health and Nutrition Evaluation Surveys (NHANES), a cross-
sectional cohort study sampling from the general population, and reported adequate 
total Mg intake levels (≥330 mg/d) to be significantly and inversely correlated to vitamin 
D insufficiency (serum 25OHD 12-20 ng/ml).35  Data from the cross-sectional study 
further indicate an inverse correlation between Mg intake and vitamin D deficiency 
(serum 25OHD <12 ng/ml) for participants with serum PTH concentrations in the 
highest (≥46 pg/ml) and lowest tertiles (<32 pg/ml).35  This finding demonstrates the 
regulatory affect of Mg on PTH secretion.  Under conditions of functional 
hypoparathyroidism and Mg deficiency, intravenous infusions of Mg can significantly 
up-regulate PTH production, raising them to normal levels.  In contrast, Mg repletion 
suppresses elevated PTH levels, as seen in secondary hyperparathyroidism resulting 
from vitamin D insufficiency.35  Most importantly, Mg intake was shown to modify low 
serum 25OHD associated risk of mortality due to CVD.35   
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Evidence of the regulatory affect of Mg on vitamin D enzymes and transport 
protein, and PTH secretion, strengthens the understanding of the role of bone regulating 
hormones and nutrients in metabolism.  The combination of low serum 25OHD, high 
serum PTH, and low Mg status is important because it represents the altered hormonal 
and nutrient milieu expected in overweight and obese individuals with metabolic 
disorders.3,35,40-44   
 
1.6 Influence of Bone Regulating Hormones and Nutrients on Energy Metabolism 
1.6.1 Bone Regulating Hormones 
Traditionally thought of as a bone-specific hormone, the noncalcemic roles of 
vitamin D were recognized with the discovery of extrarenal 1α-hydroxylase and vitamin 
D receptors (VDRs).1  Of particular interest are the autocrine, paracrine, and endocrine 
actions of vitamin D in adipose tissue, skeletal muscle, and pancreatic β-cells, all tissues 
involved in insulin-dependent control of blood glucose.  Low vitamin D levels have 
been independently associated with rickets in children and osteoporosis, as well as 
extraskeletal chronic diseases related to metabolism, such as MetS, CVD, T2DM, insulin 
resistance.35,45  Calcium and phosphorus metabolism require PTH, and hyper-secretion 
of PTH can occur with low calcium and high phosphorus intakes, common in the 
Western diet, and vitamin D insufficiency.46  The phospholipase C signaling cascade 
increases intracellular calcium concentrations and is stimulated by PTH.  With chronic 
elevations, the calcium levels within adipocytes remain high, compromising glucose up-
take and promoting insulin resistance.46   
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As of recently, reports have implicated coexisting alterations of the vitamin D 
and PTH endocrine systems as contributing to the development of metabolic 
disturbances and cardiovascular risk factors.20,40,45  Circulating estradiol (E2) synthesized 
in the ovaries maintains energy homeostasis and suppresses lipogenesis, while higher 
estrogen synthesis in adipose tissue is associated with increases in intra-abdominal fat 
deposition.28  The influence of estrogen on fat deposition may potentiate the 
development of T2DM, hyperlipidemia, HTN, and atherosclerosis.28  Osteocalcin plays a 
role in metabolism by stimulating insulin sensitivity, insulin secretion, and energy 
expenditure, while vitamin D increases production of osteocalcin.19 
 
1.6.2 Bone Regulating Nutrients 
As an essential trace mineral in the human diet, Mg plays a vital role in manifold 
physiologic processes.31,47  The primary role of Mg in metabolism is as a cofactor for rate-
limiting enzymes in glycolysis and the TCA cycle.1  Existing data indicate an inverse 
association between low Mg status, evidenced by poor dietary intake and low Mg blood 
indicators, and the presence of common metabolic abnormalities, including increased fat 
mass, insulin resistance, dyslipidemia, HTN, and inflammatory response.3,8,47,48 The role 
of vitamin D and PTH in calcium homeostasis and bone health has been profusely 
studied.  However, current investigations are deviating from this model, opting to 
instead scrutinize new insights into the relationship between these hormones and 
energy metabolism.6,9,35,40,49   
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1.7 Bone Regulating Hormones and Nutrients in Obesity  
The propensity to gain weight is multifactorial: lifestyle, genetics, environment, 
and homeostatic controls over caloric intake all contribute to varying degrees.42  
Increased fat mass has negative consequences on metabolism and bone health, despite 
the apparent benefit of increased bone mass from mechanical resistance.22  Body 
composition and patterns of fat deposition are influenced by individual differences in 
the efficiency of energy metabolism as well as modifiable factors, diet being a major 
lifestyle determinant of obesity.  This section will discuss how bone regulating 
hormones and nutrients influence metabolic outcomes in overweight and obese 
populations 
 
1.7.1 Risk Factors 
Data indicate lower average intakes of calcium, vitamin D, and Mg in overweight 
and obese populations.35,37,42  In an attempt to correct the high incidence of vitamin D 
deficiency in the United States, there has been an increase in supplementation and 
fortification yet levels remain low, particularly in those in the higher BMI categories.35  
As a major cofactor for proteins and enzymes involved in vitamin D metabolism, Deng 
et al. tested the hypothesis that serum 25OHD levels are influenced by dietary Mg, and 
risk factors of vitamin D insufficiency are thus modified.35  Data drawn from the 
NHANES cross-sectional study and the NHANES III cohort was utilized to answer this 
question.  The aforementioned results confirmed a significant and independent 
association between high total (dietary and supplemental) Mg intake and reduced risk 
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of vitamin D insufficiency and deficiency, which interacted with serum PTH levels.35  
Furthermore, data from epidemiological and observational studies indicate an inverse 
association between dietary calcium intake with abdominal obesity and total body fat, 
while higher calcium intakes from dairy products with concomitant energy restriction 
seems to enhance weight loss compared to caloric restriction alone.37  The low calcium 
intakes often occurring with increased adiposity could perpetuate lipogenesis via the 
PTH/vitamin D axis.  Both hormones increase intracellular calcium concentrations in 
adipocytes, subsequently suppressing lipolysis and activating fatty acid synthase 
activity.37  Data from a minimal number of clinical trials have demonstrated poor dietary 
intake of Mg and low serum Mg levels in overweight and obese subjects as compared to 
normal weight controls.3,8   
Higher intake of Mg-rich foods implies a better diet for weight maintenance, 
while presuming the diet adhered to by many obese individuals would be lacking good 
sources of the mineral.  Significant sources of Mg are nutrient-dense foods, such as 
legumes, dark leafy greens, and whole grains.33  Huerta et al. hypothesized that children 
with a BMI classification of overweight or obese would have lower dietary intakes and 
serum levels of Mg compared to lean children.50  Data from research of adult 
populations (BMI ≥25.0) suggest lower Mg dietary intake, but the same relationship 
between Mg and obesity had not been studied in children.50,51  The cross-sectional study 
included 24 obese, non-diabetic children and 24 lean control subjects matched for age 
and sex.  Serum Mg levels and indexes of insulin sensitivity were measured, and 
nutritional assessments were performed using the Youth and Adolescent Questionnaire 
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and the Nurses’ Health Study food frequency questionnaire (FFQ).50  The results 
revealed a significantly lower Mg status, as evidenced by dietary intake and serum Mg 
values, in the obese group.  An inverse relationship between serum Mg and fasting 
insulin was also reported, indicating a predisposal for T2DM development.50  These 
results are intriguing since serum Mg, rather than intake, more closely correlated to 
insulin resistance, suggesting a mechanistic relationship over dietary magnesium 
alone.50       
Current data also indicate a negative correlation between serum 25OHD levels 
and BMI, and an inverse relationship between serum 25OHD and other measurements 
of adiposity, such as total fat mass and WC.30,45,52,53,54  Body weight, total fat mass, and 
percent body fat (PBF) are significantly and positively correlated with PTH 
concentrations, while a significant negative correlation exists between PTH and physical 
activity, 25OHD, and dietary calcium intake.53  In a cross-sectional study with 211 female 
participants, Sukumar et al. reported high PTH levels in heavier compared to leaner 
women, and both serum 25OHD and PTH were significantly influenced by BMI.23,53 In 
the general population, a serum 25OHD concentration of 30 ng/ml has been shown to 
adequately suppress PTH secretion.45  A retrospective analysis was performed on 383 
women in all BMI categories after receiving 1-1.2 g calcium a day for one month to 
measure alterations of bone regulating hormone concentrations. The point of maximal 
PTH suppression by vitamin D was lower with obesity.  Serum concentrations remained 
stable until 25OHD fell below the threshold of approximately 11 ng/ml, correlating with 
a dramatic rise in PTH levels.45  This finding demonstrates how obesity alters the 
		
22	
relationship between PTH and vitamin D, not just in isolation, and suggests 
recommendations of beneficial vitamin D status for the general population may have 
different health indications according to adiposity.45   
Mixed recommendations for optimal levels of serum 25OHD may be explained 
by the difference in PTH suppression depending on weight classification.  Secondary 
hyperparathyroidism may play a pathogenic role in metabolic dysfunction, and studies 
done with normal weight participants or with the general population would 
theoretically show higher levels are necessary for protection against CVD than for obese 
populations.  Wang et al. performed a meta-analysis of 19 independent studies 
investigating the relationship between CVD risk factors and vitamin D status (Wang et 
al., 2012).55  After combining study results, CVD risk declined with rising serum 25OHD 
levels ranging from 8 to 24 ng/ml, while the greatest jump in risk occurred below 12 
ng/ml.55,56  Giovannucci et al. designed a nested, case-control study of 18,225 normal and 
overweight men (aged 40-75) as part of the Health Professionals Follow-up Study to 
assess the association between vitamin D status and risk of coronary heart disease 
(CHD).56  Results from the study supports the greatest risk reduction of nonfatal 
myocardial infarction (MI) or fatal CHD occurs at 30 ng/ml 25OHD.56  Higher Mg 
intakes and sufficient Mg status have the potential to ameliorate obesity-related changes 
in calciotropic hormones (vitamin D and PTH), although the predicted affect has not 
been thoroughly studied.35,41   
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1.7.2 Potential Mechanisms 
Alterations in bone regulating hormones and nutrients are consistently reported 
in overweight and obese populations.20,35,45,46,53  Whether the changes are mere indicators 
of disease or play a causative role is still being investigated.  As an antagonist of 
intracellular calcium, Mg could help to control heightened fat deposition; however, a 
direct biological influence over fluctuations in body mass and metabolism has yet to be 
established.29,42  The vitamin D endocrine system displays modifications in overweight 
and obese individuals.20,45  The high prevalence of deficiency is due in part to increased 
sequestration in excess fat; however, when considering the endocrine activities of both 
1,25{OH}2D3 and adipose tissue, the mechanistic explanation grows in complexity.20,30  
  It was recently discovered that adipocytes synthesize the major enzymes of 
vitamin D metabolism, and have VDRs displayed on their cellular membranes.30,57,58  In a 
cross-sectional study, Wamberg et al. measured the expression of enzymes and proteins 
involved in vitamin D metabolism in the fat cells of 20 lean and 20 obese women.30  
Results indicated a lower capacity to hydroxylate 25OHD in the subcutaneous fat of 
obese women compared to their lean counterparts, suggesting a lower bioavailability of 
vitamin D with increased adiposity.30,45,57  However, obese women had a 33% higher 
average concentration of nuclear VDR in their visceral adipose tissue than lean women, 
which indicates an increased sequestration despite impaired activation.30  The up-
regulation of VDR may be a cellular response to excess oxidative stress caused by 
obesity.7  Vitamin D regulates immune response and decreases inflammatory cytokines, 
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so an increased uptake of circulating 25(OH)D may be a way to combat free radical 
damage and prevent apoptosis of the adipocyte.8   
Current scientific evidence from in vitro and animal studies suggest autocrine-
paracrine effects of vitamin D in adipose tissue.2,8 As a hormone and intracellular 
secondary messenger, vitamin D could play a regulatory role in adipogenesis, inhibiting 
or promoting differentiation and proliferation of preadipocytes depending on 
conditions.8  Hyperplasia and hypertrophy of adipocytes is regulated by 1α,25(OH)2D3 
through its actions on multiple adipogenic transcription factors.  Calcitriol suppresses 
the expression of the peroxisome proliferator-activated receptor-δ (PPAR-δ), a 
transcription factor that increases adipogenesis and inhibits osteoblastogenesis.21,57  
Furthermore, data from an experimental study using mice models have shown the 
differentiation of bone marrow stromal cells into adipocytes is inhibited by liganded-
VDR suppression of multiple transcription factors in these cells.21  Investigation of the 
relationship between vitamin D and adipogenesis has accrued mixed results, so factors 
determining the regulatory actions and reduced activation of vitamin D in adipose tissue 
remain elusive.2,7  Despite indefinite conclusions, the discovery of adipocyte-derived 
VDR and hydroxylation enzymes opens the door for further insight into the common 
vitamin D alterations in overweight and obese individuals.30,57   
Considering low Mg status and elevated PTH are also associated with higher fat 
accumulations, perhaps these abberations offer another avenue for causal exploration.  
Secondary hyperparathyroidism develops as a consequence of persistently low serum 
calcium and 1,25(OH)2D.6  As previously mentioned, the resulting amplification of PTH 
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causes an influx of calcium into the blood from bone resorption and reabsorption in the 
renal tubules.41,42  As more circulating calcium is taken up by adipocytes, the higher 
intracellular concentration of the mineral can promote increased lipid storage and 
perpetuate the accumulation of fat tissue, while contributing to the vascular calcification 
contributing to CVD development.6  With this finding, McCarty et al. predicted 
secondary hyperparathyroidism to impede weight loss efforts due to decreased 
mobilization of fat storages.46   
Maintaining calcium homeostasis via the vitamin D/PTH axis is reliant on 
adequate Mg status, and those with Mg deficiency often present with the same 
metabolic disorders as those with secondary hyperparathyroidism.6  Through its 
antagonistic response to intracellular calcium influx, Mg has the capability to attenuate 
the negative effects of hypercalcemia, and possibly control heightened fat deposition.46  
A direct biological influence over fluctuations in body mass and metabolism has yet to 
be established.29,42  However, data do indicate extracellular Mg can inhibit PTH secretion 
by binding to the cell-surface calcium sensing receptors and up-regulating the 
expression of VDR on the parathyroid gland, thereby modulating the response to low 
serum calcium.1,41  The caveat to this potential protective mechanism is, under conditions 
of elevated PTH, depleted vitamin D levels, and obesity, serum Mg levels tend to be less 
than optimal and in vitro studies suggest suppression of PTH by Mg is dose dependent 
and influenced by calcium concentrations.6,35,41  There is speculation that this 
compromised Mg status could be due to decreased intake and absorption, increased 
excretion due to hyperglycosuria, or mineral wasting during enzymatic conversions.35  
		
26	
Low Mg could also be the limiting factor in vitamin D activation in adipose tissue of 
obese individuals, therefore negating the benefits of vitamin D control over 
inflammation and adipogenesis.  It has been proposed that Mg repletion can correct 
irregularities in PTH and vitamin D. 
Confirming this hypothesis would have importance on many levels, but has yet 
to be extensively studied in overweight and obese populations.35,41  Vitamin D, PTH, and 
Mg correlate independently with fat accumulation and there is evidence of the three 
playing a role in the progression of adiposity together.  The coalescence of high serum 
PTH, low circulating levels of serum 25OHD, and low Mg status characterizes the 
hormone and nutrient alterations expected with excess adiposity.6,20,59  Given the tight 
regulatory dependence of this triad, the conjunction of aberrations in vitamin D, PTH, 
and Mg levels is not surprising (Figure 1).1,35,59 
 
 
 
 
 
 
 
Figure 1. Influence of Obesity on the Relationship Between Magnesium, Vitamin D, and 
Parathyroid Hormone 
Abbreviations: iMg2, ionized magnesium; 25OHD, 25-hydroxyvitamin D; PTH, parathyroid hormone. 
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1.8 Bone Regulating Hormones and Nutrients in Metabolic Syndrome  
Previous research has shown strong independent associations between bone 
regulating hormones and varying components of metabolic syndrome, despite some 
heterogeneity in results.2,6,60  Low vitamin D, elevated PTH, and low Mg status are each 
independently associated with MetS.2,3,7,8  Higher dietary intakes of calcium have 
demonstrated a protective affect against the components of MetS, including insulin 
resistance, dyslipidemia, HTN, and chronic inflammation.37  Serum 25OHD has been 
inversely correlated to the presence of MetS, while risk for the diagnosis of MetS 
decreases with improved vitamin D status.61  Elevated WC, fasting blood glucose, and 
serum triglycerides are also associated with chronically low levels of serum 25OHD.62 
Results from a 12 week randomized, placebo-controlled clinical trial conducted by 
Harris et al. with 89 overweight or obese African American adults demonstrated 
increases insulin secretion and sensitivity with vitamin D supplementation (4000 
IU/day) compared to placebo controls in at-risk populations.49  Other studies have 
shown increased atherogenic lipoprotein and triglyceride levels occurring with primary 
and secondary hyperparathyroidism, while lowered PTH corrects these lipoprotein 
values.4,6,40  Hypomagnesemia is strongly associated with all elements of MetS, 
particularly FBG, WC, and HDL-C, as well as insulin resistance in obese individuals.3,63,64  
In a dose dependent manner, dietary intake of Mg is inversely associated with incident 
of MetS, and is strongly related to risk factors of CVD.2,34  Blood indicators of Mg have 
also been inversely correlated to FBG insulin levels, and HTN.3,64  When compiling the 
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literature, Mg status is consistently poor in obese populations compared to normal 
weight controls.2,3,6,20,50 
In a cross-sectional cohort study of 1,017 participants with class III obesity (BMI 
>40.0 kg/m2), Hjelmesaeth et al. investigated the independent effect of serum 25OHD, 
PTH, and Mg levels on the presence of MetS, and components of MetS.6  The WC for all 
participants exceeded criteria for MetS (>88cm women and >102 cm men), 68% had 
MetS, 25% had both MetS and T2DM, and 51% of participants, regardless of MetS or 
T2DM, had vitamin D insufficiency (<50 nmol/L or 20 ng/mL).  Results decisively 
revealed serum PTH levels as an independent predictor of MetS with or without 
diabetes, while suggesting a mechanistic effect of PTH on BP.6  Participants with MetS 
and T2DM had significantly lower serum Mg concentrations compared to participants 
without T2DM, which was supported by a significant correlation between Mg and 
parameters of insulin resistance. There was no significant relationship between serum 
25OHD and MetS, likely due to homogeneity of body composition among study 
participants; however, a significant correlation was noted between serum 25OHD and 
both triglycerides and HDL-cholesterol.6   
 Hjelmesaeth et al. measured and performed a multiple logistic regression 
analysis on all biomarkers of MetS, vitamin D, Mg, and PTH.6  Participants with high BP 
(≥130/85 mmHg) had significantly higher concentrations of PTH than subjects with 
normal BP (5.9 ± 2.4 pmol/L vs. 5.5 ± 2.2 pmol/L).  A linear relationship existed between 
increasing PTH levels and incidence of MetS.6  When Mg status was analyzed, a 
significant correlation to fasting glucose and insulin resistance was noted, while higher 
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vitamin D levels modified the lipid profile.6  When considered in unison, the results 
indicate PTH, magnesium and vitamin D each play a specific protective role in the 
prevention or correction of metabolic abnormalities.  Increasing magnesium intake, 
helping to balance vitamin D and PTH levels, could be beneficial in the treatment for the 
various symptoms attributed to chronic disease.8,20,35,40,42,59,  
Although these were two of the few studies with vitamin D, PTH, and Mg as 
outcome variables, only their independent effect on MetS was measured, instead of the 
integrated changes, so research is needed in this area.  Like elevated PTH, Mg deficiency 
is considered an independent risk factor for CVD, while a reduction of risk can be 
achieved through the simultaneous correction of Mg and PTH levels.4,49   Scientific 
inquiry has yet to determine whether changes in serum 25OHD levels occur with Mg 
repletion.  Since the trace mineral is intimately linked to the physiology of both 25OHD 
and PTH, an improvement in Mg status could stabilize aberrations in these bone 
regulating hormones and subsequently ameliorate the associated metabolic 
disturbances.20,40   
 
1.8.1 Hypertension 
 As Hjelmesaeth et al. reported, PTH is independently and significantly correlated 
to systolic BP (SBP) and diastolic BP (DBP) measurements, and those with elevated BP 
(≥130/85 mmHg) had significantly higher concentrations of PTH than participants with 
normal BP.6  In a 7-year longitudinal study of 1784 adults living in Norway, Jorde et al. 
discovered increases in serum PTH was a significant predictor of elevated SBP in men, 
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but not women.65  Jorde et al. did not claim a causal or mechanistic relationship between 
PTH and BP, yet hypothesized PTH could cause elevations BP from the affect of 
increased calcium reabsorption on blood osmolality.65  The authors noted it to be just as 
likely that a diet high in sodium was causing excessive calcium excretion, or low dietary 
calcium, thus raising BP and PTH for vitamin D activation and calcium reabsorption.  In 
this scenario, there is higher plausibility of low 25OHD, or high intracellular calcium in 
vascular smooth muscle cells stimulating vasoconstriction, being the causative factor in 
relation to BP.37,56,65,66   
Giovannucci et al. reported higher plasma levels of 25OHD (≥30 ng/ml) to reduce 
the risk of MI and CVD.56  One of the protective mechanisms could be the influence of 
vitamin D on the rennin-angiotensin system (RAS), which raises BP by increasing 
sodium concentrations of blood.56  After controlling for confounders (e.g. dyslipidemia, 
HTN, T2DM, smoking), 25OHD remained an independent risk factor for CVD.56  
Maintenance of BP, electrolyte balance, and body fluid volume is partially controlled by 
the RAS.  Renin is synthesized in the kidney and elevates BP by increasing renal 
absorption of sodium and expanding blood volume.67  The expression of renin is 
inhibited by 1α,25(OH)2D3 binding to VDR in juxtaglomerular cells, which then blocks 
the transcriptional activity of the renin gene element, thus modifying sodium levels and 
BP.56,67,68   
Magnesium status has been inversely associated with SBP and DBP values 
demonstrated in cross-sectional and clinical trials with Mg supplementation.33,34,69  
Extracellular Mg may have a direct influence on BP by promoting vascular relaxation, or 
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vasodilation, as a calcium-channel blocker, while low intracellular Mg in erythrocytes 
seems to impact vascular structure (e.g. arterial stiffness and thickening), leading to 
endothelial dysfunction.33,69  Animal studies have reported HTN under conditions of Mg 
deficiency.70  Findings from in vitro models suggest Mg inhibits the release of 
norepinephrine, a vasoconstrictor, by blocking calcium channels at peripheral 
sympathetic nerve endings.34  Decreases in BP may be detected through this mechanism, 
independent of the direction vasodilating action of Mg.34,69  
 
1.8.2 Glycemic Indices 
Hyperglycemia may contribute to extracellular Mg depletion.  Increased Mg 
intake seems to improve glucose homeostasis by maintaining tyrosine kinase activity for 
normal insulin signaling and secretion.2,8,29,34  As mentioned, Mg is involved in cellular 
function and metabolism on numerous levels, playing a primary role in both 
carbohydrate and lipid metabolism.1  In order to further investigate how Mg may 
protect against MetS, Sales et al. designed a preclinical study to test the metabolic effect 
of a high-fat diet compared to a magnesium-deficient high-fat diet using 48 male rats.29  
Results demonstrated that Mg intake does not prevent weight gain, but does slow the 
progression of insulin resistance.  A high-fat diet promoted insulin resistance as 
expected while sufficient Mg seemed to correct this aberration.29  Assessment by 
Western blot revealed decreased phosphorylation of proteins involved in the 
intracellular insulin-signaling cascade in the Mg-deficient group.  Therefore, the 
subsequent reduction of insulin secretion by pancreatic β-cells was possibly due to 
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insufficiently met requirements of Mg-ATP necessary for the process.29  Magnesium 
deficiency could also cause diminished receptor tyrosine kinase activity, thus blunting 
cellular response to insulin binding. With the resulting impairment in the of glucose 
transporter 4 (GLUT4) translocation, glucose uptake into skeletal muscle or adipose 
tissue would be reduced.54  This evidence suggests Mg is influential in maintaining 
insulin sensitivity, and deficiency may promote insulin resistance.54   
In contrast, serum calcium positively correlates to insulin resistance and fasting 
glucose, which is likely due to low dietary intake of calcium.46  Elevated PTH in response 
to low calcium absorption in the intestine will prompt an influx of calcium into 
circulation from bone resorption and renal reabsorption.37  When PTH binds to its 
receptor on adipocytes, there is an activation of heterotrimeric G proteins and 
stimulation of phospholipase C-β signaling cascade, causing an influx of calcium into 
the cell.46  High intracellular calcium inhibits the dephosphorylation of GLUT4, 
diminishing insulin response in adipose tissue.37,46  Without adequate Mg levels or 
dietary calcium to help control intracellular calcium concentrations, translocation of 
GLUT4 is further reduced and metabolic efficiency is compromised.46  The detrimental 
affect of high intracellular calcium may be why the combination of low Mg status, low 
dietary calcium, and high PTH often coincide with insulin resistance.  Low vitamin D is 
also associated with reduced expression of insulin receptors and impaired 
dephosphorylation of GLUT4 subsequent to insulin binding.45,49,52,67   
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1.8.3 Lipid Profile 
Gaining insight into the causative role of Mg and dietary calcium in dyslipidemia 
has been difficult, largely due to the heterogeneity between study results and sample 
populations (Randell et al., 2008; Torres et al., 2012).36,37  Low ionized and serum Mg are 
negatively correlated with triglycerides, total cholesterol, and LDL-C, and positively 
correlated with HDL-C in populations with T2DM and MetS.  This same atherogenic 
lipid profile has been positively correlated to serum calcium, while an inverse 
relationship exists between dietary calcium and Mg in obese individuals with 
dyslipidemia.36,37  Unexpectedly, the opposite change in serum Mg has been reported in 
lean populations.  Randell et al. observed serum Mg to correlate positively with serum 
calcium, triglycerides, LDL-C, HDL-C and total cholesterol in a population of 1318 
healthy adults recruited from Newfoundland, Canada.36  
In a study of the Chinese population conducted by Yu et al., participants with 
hyperlipidemia, obesity, and hypertension were reported to have higher levels of serum 
Mg compared to healthy controls.70  However, data revealed an abnormal free fatty acid 
composition in participants with MetS components and elevated serum Mg 
concentrations.70  This finding of a high proportion of circulating saturated FAs and low 
estimated desaturase activity led to the hypothesis that those with MetS may be 
consuming a more Westernized diet, therefore dyslipidemia is observed in a different 
form.  Depleted Mg has been shown to decrease desaturase activity in animal models, 
thus altering lipid metabolism, which may be displayed in different ways depending on 
ethnic and dietary variance between populations.70 Low Mg may impair inactivation the 
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rate-limiting enzyme in cholesterol synthesis or Increases lipoprotein lipase activity.36  
Secondary parathyroidism promotes insulin resistance, possibly potentiating loss of β-
cell function, but also decreases fatty acid oxidation via the same mechanism.  The 
increases of intracellular calcium as a result of low dietary intake and high PTH may 
blunt the ability of catecholamines to activate lipolysis.36,37 A direct relationship between 
PTH and dyslipidemia has not been established, yet a triglyceride lowering effect with 
reduced PTH has been reported perhaps mediated by increases in dietary calcium.7,37 
Hjelmesaeth et al. reported serum levels of 25OHD to significantly correlate with 
triglycerides and HDL-cholesterol.6  Evidence supporting the role of vitamin D in 
adipogenesis is convincing, yet few studies have examined a causal relationship with 
dyslipidemia.6  Yin et al. designed an experimental animal study to gain further insight 
into the possible physiologic mechanisms involved.71  Yucatan microswine were fed a 
diet high in cholesterol for 48 weeks while kept vitamin D deficient (0 IU/d), sufficient 
(1000 IU/d), or supplemented (3000 IU/d).  Results indicated a decrease in HDL-C in 
vitamin D deficiency, and vitamin D seemed to control cholesterol efflux from the liver.71  
 
1.8.4 Inflammatory Markers 
Failing to address systemic inflammation when discussing obesity and metabolic 
abnormalities is misguided, as the excessive oxidative stress associated with MetS 
ultimately perpetuates symptoms to the point of chronic disease.1,2  Levels of pro-
inflammatory cytokines, such as CRP, are measured as a clinical diagnostic tool for 
gauging oxidative stress, one of the contributors in the development of metabolic 
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abnormalities.2  Surfacing evidence points to a Mg-rich diet as a strategy to reduce 
inflammatory response.  In a cross-sectional analysis of 11,686 women, Song et al. 
reported a significant inverse association between a Mg intake of 326 mg/day, slightly 
above the RDA, and plasma concentrations of CRP.2  The antioxidant effect of Mg was 
more evident in participants within the higher BMI range.  Lowered fasting insulin 
levels were detected in subjects with increased Mg intake, which could be a secondary 
benefit to the control of oxidative stress.2   
The mechanisms behind the effect of Mg on low level chronic inflammation are 
inconclusive, clearly warranting further investigation.  However, evidence supporting 
vitamin D as a regulating agent in immune response and inflammatory reactions is 
strong, prompting the question of synergistic action.57   Calcitriol inhibits the activation 
of Nuclear Factor kappa-B (NF-κB) and mitogen-activated protein kinase (MAPK) 
signally pathways, thereby preventing transcription and secretion of certain pro-
inflammatory cytokines, such as monocyte chemoattractant protein-1 (MCP-1), 
interleukin-6 (IL-6), interleukin-8 (IL-8).57 Magnesium enhances the availability of 
1α,25(OH)2D, helping to meet the cellular needs to counteract inflammatory response 
under conditions of obesity and metabolic abnormalities.57  Low level chronic 
inflammation in obesity, insulin resistance, and MetS.  Unlike the relationship between 
vitamin D and PTH, the clustered associations of Mg with these parameters has been 
given little attention to date in the scientific community, highlighting the need to delve 
further into a mechanistic understanding.6 
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1.9 Characterizing the Metabolically Healthy Obese Phenotype 
1.9.1 Protective factors and bone regulating hormones and nutrients 
Understanding the influence of bone regulating hormones and nutrients on 
metabolism may lead to new ways of characterizing the MHO phenotype.  With varying 
degrees of influence, some of the proposed protective factors include physical activity 
level, stress management, subcutaneous versus visceral fat, fat depostion, duration of 
obesity, PBF, age, ethnicity, genetics, diet, and possibly the triad of low vitamin D, high 
PTH, and low Mg status.  In one of the few investigations of the relationship between 
Mg status and the MHO phenotype, Guerrero-Romano et al. conducted a study with a 
population-based, cross-sectional design comparing serum Mg levels in obese and lean 
participants.3  The 427 adults aged 20-65 were allocated into four subgroups according to 
weight and presence of metabolic abnormalities: the metabolically obese normal weight 
(MONW) subgroup, the MONW control subgroup, the MHO subgroup, or the MHO 
control subgroup.3  The results indicated that a Mg deficiency is positively correlated 
with the MONW phenotype, while there was an inverse relationship between 
hypomagnesemia and individuals exhibiting signs of MHO.3  It remains unclear if 
dietary intake is the primary factor or if Mg plays an etiologic role in metabolic 
abnormalities regardless of weight.50  In the United States, rates of noncommunicable 
chronic disease are rising.  At the same time, daily dietary intake of Mg has decreased by 
60% since the last century, most adults falling short of the Recommended Dietary 
Allowances (RDAs) for their gender and age.33  It is recommended that men receive 400-
420 mg of Mg per day, while women should obtain 310-320 mg daily from their diet.1  
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Magnesium-rich foods are largely plant-based, such as dark greens, legumes, nuts, and 
whole grains, an increase in processed foods the likely culprit displacing these healthy 
sources.33,48  Despite a scarcity of knowledge about the potential mechanisms, Mg seems 
to be an important factor in the prevention of chronic disease.41  Dietary or supplemental 
Mg could be used to increase the efficacy of nutritional therapy for the prevention of 
metabolic abnormalities often resulting from obesity.3,41   
Results from a clinical study conducted by Rodriguez Moran et al. demonstrated 
how normal weight adults with ≥1 symptoms of MetS have low dietary and serum 
concentrations of Mg, while supplementation with Mg corrects metabolic 
abnormalities.31  Recent data suggest that individuals with the MHO phenotype have a 
higher Mg status compared to their counterparts, indicating this essential trace mineral 
as a possible protective factor.3,18  Current scientific understanding has yet to establish 
Mg status as an important contributing factor in the characterization of the MHO 
phenotype.  Given the coexistence of biological pathways, it is important to integrate the 
influence of Mg over vitamin D and PTH when considering the physiologic design of 
protection against metabolic abnormalities.2-4,6,7,49  The mechanisms of Mg involvement in 
the MHO phenotype are not yet clear and its actions in accordance with vitamin D and 
PTH have not been thoroughly examined in other studies.  The goal of this study is to 
investigate how metabolic abnormalities in overweight and obese individuals are 
distinctly influenced by bone regulating hormones and nutrients.  Vitamin D, PTH, and 
Mg are all independent risk factors for MetS, while simultaneous alterations in all three 
could be a synergistic risk factor for components of MetS.  In the current study, we 
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propose MHO individuals will have normal levels of vitamin D, PTH, and Mg, and 
MUO individuals will have the following triad of metabolic alterations: Low dietary 
intake and blood indicators of Mg, low dietary calcium, low serum levels of 25(OH)D, 
and elevated PTH or hyperparathyroidism (See table 3).   
 
 
Table 3: Bone Regulating Hormones and Nutrients in predicting the MHO and MUO 
phenotype 
  
MHO 
 
MUO 
 
Measure 
 
Sufficient 
 
Increased Risk 
 
Magnesium Intake (mg/d)1,33 
  
 Men (≥19 years) 420 <250 
 Women (≥19 years) 320 <250 
 
Blood Indicators of Magnesium status54 
  
 Serum Mg (mg/dL) >1.8 ≤1.5 
 Serum iMg2+ ≥0.6 <0.6 
 
Calcium Intake (mg/d)37 
  
 Men (≥19 years) 1200 <500 
 Women (≥19 years) 1200 <500 
 
Vitamin D status56 
  
 Serum 25OHD (ng/ml) ≥20 <20 
 
Parathyroid Hormone40 
  
 Serum PTH (ng/L) 12-55 >55 
Abbreviations: MHO, metabolically healthy obese; MUO, metabolically unhealthy obese; Mg, magnesium; iMg2+, ionized 
magnesium; 25OHD, 25-hydroxyvitamin D; PTH, parathyroid hormone;. 
 
 
 
Despite being overweight or obese, MHO individuals exhibit no additional 
metabolic complications, placing them at lower risk for chronic disease.4,7  Fat 
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distribution, insulin sensitivity, genetics and physical activity may all be protective 
factors contributing to this healthier subclass.3  The study of this population may further 
our understanding of the phenotypic differences in existence and reveal the protective 
mechanisms involved.  Beginning to characterizing the MHO phenotype with bone 
regulating hormones and nutrients (See table 4) may unlock and pioneer new, cost 
effective therapeutic approaches, other than weight reduction, to correct risk factors 
associated with dysfunctional energy metabolism.  And perhaps elucidate the 
mechanisms at work within biochemical pathways contributing to excess adiposity and 
metabolic abnormalities in the first place.   
 
 
 
Table 4: Characterization of the MHO Phenotype 
 
Serum Marker 
 
MHO 
 
MUO 
 
Serum iMg2+ 
 
Normal 
 
Low 
 
Serum 25OHD 
 
Normal 
 
Low 
 
Serum PTH 
 
Normal 
 
High 
Abbreviations: MHO, metabolically healthy obese; MUO, metabolically unhealthy obese;  
iMg2+, ionized magnesium; 25OHD, 25-hydroxyvitamin D; PTH, parathyroid hormone. 
 
 
 
1.9.2 Defining the Metabolically Healthy Obese Phenotype 
There is no standard definition of MHO, so for the purposes of our research, 
MHO will be defined as those with a BMI of ≥25 kg/m2 and WC of <102 cm for men and 
<88 cm for women.  Data consistently indicate smaller WC in MHO individuals and is 
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used in the definition for most studies.  A cross-sectional pilot study will be conducted 
to determine if adequate Mg status and bone regulating hormones characterize the 
MHO phenotype, based on our definition. 
 
 
1.10 Rationale and Significance 
A greater understanding of the MHO phenotype in relation to bone regulating 
nutrient status such as Mg and calcium and bone regulating hormones such as PTH and 
vitamin D could reveal the protective factors involved in their superior health status.  
The research proposed here will explore the relationship between vitamin D, Mg, and 
PTH, and their synergistic influence on metabolic abnormalities in overweight and obese 
individuals.  Our findings could help characterize the MHO phenotype, gain new 
insight into the endocrine functions of bone and adipose tissue, and promote further 
investigation of the biochemical mechanisms involved in the protection against 
metabolic abnormalities.   
 
CHAPTER 2. EXPERIMENTAL APPROACH 
2.1 Study Population 
2.1.1 Sample Size  
The goal is to recruit individuals with a BMI in either the overweight or obese 
category for our cross-sectional pilot study. These participants will be classified as MHO 
or MUO using our definition based on body fat. 
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2.1.2 Inclusion Criteria 
1. Male or female with a BMI > 25.0 kilograms/meters2 
2. Age 18-70 years of age 
3. Signed informed consent 
2.1.3 Exclusion Criteria 
1. Individuals with diabetes mellitus 
2. Individuals with cancer or cancer therapy in the past year 
3. Individuals with kidney disease or kidney stones in the past year 
4. Individuals with immune disease or on steroid drugs to suppress immunity 
5. Individuals with unmanaged thyroid disease 
6. Individuals with heart attack or stroke within the past year 
7. Individuals with arthritis taking prednisone 
8. Individuals with liver disease 
9. Female participants who are pregnant or planning to become pregnant 
10. Individuals undergoing hormone replacement therapy 
11. Individuals on osteoporosis medication 
12. Individuals taking magnesium supplements 
13. Individuals taking diuretics 
14. Individuals taking vitamin D supplements 
Participants must meet the inclusion criteria and free of all mentioned conditions to be 
included in the study. 
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2.2.4 Study Groups 
We will allocate all eligible participants into one of two groups: a Metabolically 
Healthy Obese (MHO) group and a Metabolically Unhealthy Obese (MUO) group 
(Figure 2). 
 
Figure 2. Allocation of Participants 
Abbreviations: BMI, body mass index. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Study 
Participants
n = 27 
Metabolically 
Healthy Obese 
Group
% Trunk Fat: 
< 19.2%
BMI: 
≥ 25.0 kg/m2
Metabolically 
"Unhealthy" 
Obese group
% Trunk Fat:
≥ 19.2%
BMI:
≥ 25.0 kg/m2
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Table 5: Outcome Variables 
 
Main Outcome Variables 
 
Distal Outcomes 
 
Magnesium 
 
Free iMg2+ fraction and serum 
Mg 
 
Body Mass Index 
 
Dietary Magnesium 
 
Mg-FFQ 
 
Waist Circumference 
 
Dietary Calcium 
 
24-hr Dietary Recall 
 
Blood Pressure 
 
Vitamin D 
 
Serum 25OHD 
 
Serum Insulin and glucose 
 
Parathyroid Hormone 
 
Serum PTH 
 
Lipid Profile 
 
Body Composition 
 
% Body fat and Trunk Fat 
 
Abbreviations: iMg2+, ionized magnesium; FFQ, food frequency questionnaire; PTH, parathyroid hormone. 
 
 
CHAPTER 3. STUDY PROCEDURES 
 
3.1 Recruitment and Enrollment 
Study participants will be recruited by hanging advertisements around the 
Drexel University Center City Campus and Hahnemann University Hospital (Appendix 
A).  The institution’s human resources department will approve and stamp the posted 
flyers.  The advertisement will describe the research objective, as well as the subject 
eligibility, requirements, and compensation.  Study candidates will contact the research 
team via the email address provided on the flyer.  Once contacted, an initial telephone 
screening will be scheduled in order to verify eligibility.  The researcher will call the 
candidate at the scheduled time in order to complete a brief medical history form will be 
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completed, confirming current medications and treatments, and a lack of exclusion 
criterion.  During the screening, the individual’s BMI will be calculated by dividing their 
weight in kilograms (kg) by their height in meters squared, using the weight and height 
the candidate provides.  We will include those who fall slightly below the classification 
of overweight in case their reported weight is underestimated.  If the BMI calculation 
categorizes them as overweight (24.5-29.9 kg/m2) or obese (30-40 kg/m2) and they fall 
within the required age range (18-70 yrs), the screening will continue to account for 
remaining inclusion and exclusion criteria.   
Once eligibility has been established, the study requirements will be explained.  
If the individual chooses to participate, the researcher will schedule the study visit, 
which consists of a consenting process, Mg Food Frequency Questionnaire (FFQ), fasting 
blood draw, anthropometric measurements, blood pressure measurement, and dual 
energy x-ray absorptiometry (DXA) scan.  All procedures will take place at the 3 
Parkway research laboratories at 1601 Cherry Street, Philadelphia, PA 19101 in a single 
appointment, unless the participant opts to schedule their DXA for a different day.  As 
an incentive to participate in the study, participants will receive monetary compensation 
at their visit.   
3.2 Informed Consent 
The study participant will arrive for their baseline visit, which will begin with an 
overview of the informed consent.  A thorough explanation of the study requirements 
will be given.  The participant will be asked if they understand and if they have any 
questions.  They will initial each page and sign and date the back.  A copy of the consent 
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will be given to the participant.  Medical history and current medications will be 
obtained after the consent is signed.  Once these steps have been completed, the 
necessary measurements will be collected for the remainder of the visit.   
 
3.3 Study Questionnaires 
3.3.1 Medical History 
Completion of the medical history form will require the following information: 
race, date of birth, contact information, disease history, tobacco and alcohol use, recent 
and current medications, eating disorder diagnosis, any medical concerns, and any 
recent weight loss/gain greater than 10lbs. 
 
3.3.2 Magnesium Food Frequency Questionnaire 
Participants will sign an informed consent prior to completing the magnesium 
food frequency questionnaire validation study.  The questionnaire was designed by a 
research team of Drexel University undergraduate nutrition students, and is still in the 
process of being validated.  Previous research has deemed food frequency 
questionnaires (FFQs) as a reliable method for assessing the average intake of Mg-rich 
foods and estimating specific nutrients in the diet.72 Previous studies have demonstrated 
the value of well-designed and validated FFQs for their accuracy in determining average 
intakes of dietary magnesium.2  Participant will answer questions on the Mg FFQ 
(Appendix B) regarding their intake of foods highly concentrated with Mg, yet they will 
not be made aware of why the questionnaire focuses of certain foods.  Typical serving 
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size and frequency of intake will be obtained for the particular foods that are consumed 
by the participant. 
 
3.3.3 24-Hour Dietary Recall 
The participant will answer questions about their food intake from the previous 
day for a 24-hour dietary recall to compare to their FFQ and assess dietary calcium 
intake.  While acknowledging the drawbacks and qualitative nature of dietary 
assessments, multiple studies have demonstrated 24-hour recalls are one of the best 
tools for evaluating intakes of energy, protein, and various micronutrients with energy 
estimations being the least reliable.73  We are interested in a snapshot to compare to FFQ 
to validate how much Mg the participants typically consume.  Serum calcium is tightly 
controlled by calciotropic hormones, making dietary evaluation a better indicator for our 
purposes.1  
 
3.4 Physiological and Anthropometric Measurement 
3.4.1 Height and Weight 
The participant’s weight and height will be measured and recorded in the subject 
file.  Weight will be measured with minimal clothes and shoes off to the nearest 0.5 kg 
using a Seca 700 Physician’s Balance Beam Scale, Chino, CA, USA.  A stadiometer 
attached to the scale will be used to assess height to the nearest quarter inch. Body mass 
index will then be recalculated to verify the value is ≥25.0 kg/m2. 
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3.4.2 Waist Circumference 
Waist circumference will be obtained by wrapping a non-stretch tape measure 
[Health Mobius® Circumference (Girth) measuring Tape-Body Tape Measure] around 
the torso one inch above the umbilicus, measuring to the nearest quarter inch.   
 
3.4.3 Blood Pressure 
A registered nurse will obtain the participant’s systolic and diastolic blood 
pressure using a sphygmomanometer, measuring to the nearest 0.5mmHg. 
 
3.4.4 Dual Energy X-ray Absorptiometry 
Body composition will be measured from dual-energy x-ray absorptiometry 
(DXA), a total body scanner (GE-Lunar).  This clinical assessment tool can detect PBF, 
total fat mass, and percentage of android versus gynoid fat deposition, eliminating the 
need for a body CAT Scan (CT) or magnetic resonance imaging (MRI) machine.74  A 
study performed by Sasai et al. verified that the use of DXA provides an accurate 
measurement of fat percentage with minimal radiation exposure, unlike a CT scan.74 
More commonly, DXA is used to assess BMD and bone mineral content at important 
anatomical sites, such as dual-femur, lumbar spine, femoral neck, trochanter, and total 
body.75  For the purpose of our study, only the body composition measurements will be 
recorded. 
Participants will have the option to complete a DXA during the initial visit, or 
return within the same week.  An email will be sent to the participant prior to their 
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scheduled DXA visit, advising them to wear loose clothing free of any metal 
components (i.e. no jeans, underwire bras, snaps, etc.).  A member of the research team 
will perform the DXA measurements. As a precaution against prenatal radiation 
exposure, all female participants will be asked to take a urine pregnancy test (Fisher 
HealthCare™ Sure-Vue™ Serum/Urine hCG Test) prior to receiving a DXA scan. 
 
3.5 Biochemical Measurements 
3.5.1 Venipuncture 
Blood samples from each participant will be collected in the phlebotomy lab at 
the 3 Parkway building using a 23-gauge venipuncture.  It will be verified that the 
subject has been on an eight hour fast, avoided coffee, and is well hydrated prior to the 
blood draw.  A total of three tubes of blood will be filled to the top, including one 
sodium-heparin tube (BD Vacutainer™ Plastic Blood Collection Tubes with Sodium 
Heparin: Hemogard) and two serum separation tubes (BD Vacutainer™ Venous Blood 
Collection Tubes: SST™ Serum Separation Tubes: Conventional Stopper).   
Once obtained, the blood will be kept upright at room temperature for at least 
one hour prior to being centrifuged at 1400 g for 12 minutes.  The samples will be 
transported to the Drexel biochemical lab at 3711 Market Street for centrifuging with an 
arrival time of <5 hours.78,79 Using a micropipette, serum each of the tubes will be 
aliquoted into 3 vials in 100 mL increments.  The serum from the serum separation tubes 
will be stored at -80°C until blood has been collected from all participants.  The samples 
will be held together in timely manner to be tested in batch analysis at the Nutritional 
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Biochemistry Center for Excellence at Drexel University. Serum concentrations of 
ionized Mg, calcium, and sodium will be measured via an Ion Sensitive Electrode 
Method by the NOVA-8 analyzer (NOVA 8 analyzer, NovaMedical, MA) located in the 
Drexel biochemical lab.  Serum from the Na-heparin tube will be used for this 
biochemical measurement because Na-heparin is an anti-coagulant and has low cation 
concentration, limiting contamination of the sample.79  
 
3.5.2 Biochemical Indicators of Magnesium 
Free ionized Mg (iMg2+) will be measured using an Ion Sensitive Electrode 
Method with the NOVA-8 analyzer (NOVA 8 analyzer, NovaMedical, MA).  Greenway 
et al. tested the stability of iMg2+ for different lengths of time and under varying 
conditions.79  Results confirmed there were no significant changes to serum iMg2+ 
concentrations in whole blood iMg2+ left at room temperature in a capped tube over a 
period of 6 hours.79  To avoid iMg2+ degradation, the blood samples will be centrifuged, 
aliquoted, and analyzed by the NOVA-8 analyzer in <5 hours.79  As the biologically 
active form, iMg is a more reliable indicator of Mg status than serum Mg, which can 
show deceptively high levels with antacid intake or renal failure.1 Since most of the Mg 
found in the human body is compartmentalized within cells and bone, it is difficult to 
perform a clinical assessment of total body Mg.1  Variability of extracellular free iMg2+ 
reflects variability of intracellular concentrations.  Since they are in equilibrium, iMg2+ in 
serum is a good indicator of bioavailability and status.79  Serum Mg is the adequate 
analytic tool used in clinical settings and studies, so this value is often utilized in 
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research studies as an adequate marker of Mg status.1,38  Both measurements will be 
taken to enhance accuracy of the assessment, and to provide data to more easily 
compare to other study results.60  Magnesium status will be determined using the serum 
and ionized measurements and FFQ results, values that are expected to reflect each 
other.79  
Principle: Nova Analyzers use ion selective electrode technology to measure 
ionized minerals and electrolytes in whole blood, plasma, and serum. The components 
include a sensing ion-selective membrane, a reference solution provided by the sample, 
and an internal filling solution a fixed concentration of the ion in question. The 
magnitude of the electrical potential is measured using a electrode that measures the ion 
concentration difference between the two sides of the membrane (University of 
Michigan, 2016).80 
 
3.5.3 Measurement of Parathyroid Hormone and Vitamin D levels 
The measurements for serum PTH and 25OHD will be done using Enzyme-
linked Immunosorbent Assays (ELISA) at Drexel University.  Once blood samples from 
30 participants have been obtained, a batch analysis of the stored serum will be 
performed in order to reduce spending on the high cost of the ELISA.  
PTH Principle: Serum PTH samples will be analyzed using an Intact PTH ELISA 
(1-84) assay with 6 microwells.  The structure of PTH (1-84) contains a C and N terminal 
region two different goat polyclonal antibodies to human PTH for specific well-defined 
regions of the molecule.  There is a type of goat polyclonal antibody that binds to the 
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mid-region and C-terminal PTH 39-84 while the another binds to the N-terminal PTH 1-
34, forming a detectable complex with PTH 1-84. This second antibody is labeled with 
horseradish peroxidase for detection.  After an incubation period with the labeled 
antibody, unbound components are washed away from the microwell and the enzyme 
bound to the solid phase is incubated with the substrate, tetramethylbenzidine. An acid 
stop solution changes the color of the sample to yellow and the intensity of this yellow 
color is directly proportional to the concentration of intact PTH (1-84) in each sample. 
The intact PTH in the controls and participant samples can be examined using a dose 
response curve (ALPCO, Salem, NH, USA).  Coefficient of variance (CV): Intra-Assay 
CV: 6.08%; Inter-Assay CV: 3.6% 
25OHD Principle: 25OH-Vitamin D direct ELISA kit will be used to determine 
serum 25OHD levels in human participants (ALPCO, Salem, NH, USA). This assay 
recognizes 25OHD levels with a monoclonal antibody. The serum samples are incubated 
with a releasing agent to allow for release of 25OHD from the 25OHD, vitamin D 
binding protein complex. The solution is then transferred to a microplate with a 25OHD 
coating and an anti-25OHD antibody is added. After an overnight incubation period, a 
peroxidase-conjugated antibody is added, which forms a complex of 25OHD, anti-
25OHD antibody, and peroxidase conjugate. Tetramethylbenzidine is used as a 
peroxidase substrate and an acidic stop solution is added to stop the reaction, turning 
the solution from blue to yellow. The intensity of the yellow is inversely proportional to 
the 25OHD concentration of the sample. The standard 25OHD from the samples can 
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then be determined from a dose response curve of absorbance unit versus concentration 
(Immunodiagnostic Systems Inc.).  Coefficient of variance (CV): Total: 11.6% 
 
3.5.4 Glycemic Indices 
Commercial enzyme-linked immunosorbent assay [R&D Systems™ Insulin 
(Human) ELISA Kit] will be used to assess serum insulin levels and the hexokinase 
method for the measurement of fasting glucose levels (Thermo Scientific™ Glucose 
Hexokinase Reagents). Intra-Assay CV: 6.0%; Inter-Assay CV: 9.0%  
 
3.5.5 Lipid Profile 
A complete lipid profile, including serum concentrations of total cholesterol, 
high-density lipoproteins (HDLs), low-density lipoproteins (LDLs), and triglycerides 
will be processed and analyzed at the Nutritional Biochemistry Center for Excellence at 
Drexel University.  Cholesterol will be measured with a cholesterol assay (Abnova™ 
Cholesterol Assay kit), which detects free cholesterol and cholesterol esters (Intra-Assay 
CV: 2.5%; Inter-Assay CV: 4.5%).  Lipoproteins will be measured using a HDL and 
LDL/VLDL Cholesterol assay (Abnova™ HDL and LDL/VLDL Cholesterol Assay kit) 
with an intra-assay CV of 4.1% and inter-assay CV of 7.2%, and serum triglycerides will 
be measured using a different assay (Abnova™ Serum Triglyceride Quantification Kit).  
Intra-Assay CV: 1.5%; Inter-Assay CV: 1.5%  
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CHAPTER 4. STATISTICAL METHODS 
Study participants will be allocated into one of two groups according to median 
percent trunk fat: the MHO group (<19.2% trunk fat) or the MUO group (≥19.2% trunk 
fat).  Participants will be weight matched and age matched in both groups. The means 
and standard deviations for all collected measurements (age, height, weight, WC, BMI, 
PBF, total body fat, lipid profile, glycemic indices, Mg intake, calcium intake, iMg2+, 
serum Mg, 25OHD, and PTH) will be calculated using descriptive statistical 
procedures.77 Logistic regression analysis and Pearson product moment correlation will 
be used to identify possible associations between Mg status and prevalence of metabolic 
abnormalities.77  Correlational significance, or strengths of relationships between 
variables, will be reported to the 95% confidence intervals.2,31  One way ANOVA will be 
used to determine whether a statistically significant difference exists between the groups 
for serum, ionized, dietary Mg and other bone regulating hormones.  Multiple linear 
regression analysis will determine if dietary, serum and ionized Mg can predict vitamin 
D and PTH levels in both groups and association between Mg status and MHO variables 
will be measured with a correlation analysis.  Finally, multiple logistic regression 
analysis can be used to establish relationship between Mg status (dependent variable) 
and the prevalence of metabolic abnormalities.  The IBM SPSS statistics software (IBM 
SPSS Statistics for Windows, Version 22.0. Armonk, NY: IBM Corp) will be used to 
calculate all statistical parameters.2  Scatter plots will be created as visual aids 
representing the significant correlation between variables with a line of regression.60   
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Interpretation of data will help determine whether the results of the study 
support or disprove the study hypotheses and research problems.60 The data analysis 
will be compared to the existing evidence and body of knowledge.  If the study results 
confirm previous findings, the validity of the efforts and claims will increase.  Therefore, 
there is a better chance statistical significance can be translated into practical 
significance, perhaps in the form of therapeutics advancements in the treatment of 
metabolic abnormalities.60  The common characterization of the MHO phenotype is 
obesity with <2 metabolic aberrations used to diagnose metabolic syndrome.  Our 
characterization of the MHO phenotype will have the additions of serum Mg, PTH, and 
vitamin D (See table 6). 
 
Table 6: Current and Predicted Characterization of the MHO Phenotype 
 
Parameter 
 
MHO 
 
MUO 
Overweight/obese (kg/m2) 25.0-29.9/30.0-40.0 25.0-29.9/30.0-40.0 
Waist Circumference (cm) <102 (M); <88 (F) ≥102 (M); ≥88 (F) 
Blood Pressure  Normal Abnormality likely 
Fasting Blood Glucose Normal Abnormality likely 
Triglycerides Normal Abnormality likely 
HDL-cholesterol Normal Abnormality likely 
Magnesium Status Normal Lower 
Dietary Calcium Normal Lower 
Vitamin D Normal Lower 
Parathyroid Hormone Normal Elevated 
Abbreviations: MHO, metabolically healthy obese; MUO, metabolically unhealthy obese; M, male; F, female; HDL, high 
density lipoprotein. 
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CHAPTER 5. RESULTS AND DISCUSSION 
5.1 Introduction 
Adults with a body mass index (BMI) categorized as overweight (25.0-29.9 
kg/m2) or obese (≥30.0 kg/m2) are considered to be at higher risk of developing a 
multitude of health complications.1  Extensive research has demonstrated how those 
with excessive adiposity commonly present with a cluster of distinct comorbidities, 
including hypertension (HTN), insulin resistance, and dyslipidemia.1-3,31  These 
metabolic abnormalities often double the risk of developing cardiovascular disease 
(CVD) and amplify the risk for type 2 diabetes mellitus (T2DM) by five-fold.4,5   
With multiple components of MetS comes increased risk of CVD, T2DM, and 
osteoporosis.1,6  Ample evidence supports the interconnectedness of the seemingly 
isolated metabolic disturbances of increased abdominal fat, lipid metabolism, glucose 
uptake, and elevated BP.1,3,6  Imbalances in one metabolic pathway interrupt other 
physiological processes, leading to a vicious self-generating cycle of disrupted enzyme 
regulation, metabolic dysfunction, and disease development.4,7,8 
Although obesity is frequently associated with metabolic abnormalities and 
viewed as a homogenous condition, an important subgroup within the overweight and 
obese populations who lack the expected comorbidities despite their predictive body 
composition is now being recognized.3,4,7,10  The term metabolically healthy obese (MHO) 
phenotype originated to describe the phenomenon of obesity with a benign metabolic 
status, although individuals categorized as overweight (BMI 25-29.9 kg/m2) are often 
included in the subgroup.4,7,10 To be considered MHO, an individual is largely free of the 
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common risk factors of CVD despite a BMI (kg/m2) classification of overweight or 
obese.11  In an effort to characterize the MHO phenotype and map the health benefits 
experienced by the subgroup, numerous studies have investigated possible protective 
factors and how risk of disease compares to metabolically unhealthy obese (MUO) 
individuals in all weight categories.  While there is no standard definition of MHO, most 
sample populations are categorized according to the absence of MetS or the complete 
absence of all components of MetS (See table 2).     
Strong consistencies in study results outweigh conflicting evidence, offering new 
insight into the level of protection against disease.  The MHO phenotype seems to be 
protective against systemic inflammation evidenced by normal levels of CRP and 
smaller WC, both indicators of visceral adiposity.10,16 In addition, higher insulin 
sensitivity is consistently found in MHO individuals, thus lowering risk for developing 
T2DM.  When analyzed together, previous studies suggest the MHO phenotype has a 
risk factor for CVD between that of normal weight healthy and MUO individuals.  When 
analyzed together, previous studies suggest the MHO phenotype has a risk factor for 
CVD between that of normal weight healthy and MUO individuals.  The MHO 
individual is still at increased risk for CVD and all-cause mortality compared to healthy 
lean counterparts, but will develop chronic disease more slowly than MUO.10  The goal 
of characterizing the MHO phenotype is not to postpone weight loss, but rather to 
determine protective mechanisms against metabolic abnormalities until weight loss can 
be achieved.10,16 
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 A small assemblage of studies examined the influence of bone regulating 
hormones and nutrients in the development of metabolic abnormalities coinciding with 
excess adiposity.  Previously thought to be static tissues, the recent acknowledgement of 
bone and adipose tissue as endocrine organs has been a prominent revelation in human 
health.3,19,20  Emerging evidence has confirmed the dynamic hormonal activities of 
vitamin D, parathyroid hormone (PTH), estrogen, and osteocalcin, as well as the role of 
protein, calcium, and magnesium (Mg), in metabolic processes and bone integrity.22-24 
The parathyroid gland produces parathyroid hormone (PTH), which couples 
with vitamin D in the homeostatic control of calcium and phosphorus.1  These two bone 
regulating hormones function in a negative feedback loop.  When serum calcium levels 
are low, PTH secretion increases to stimulate the final activation of vitamin D in the 
kidneys to its hormonal form for assistance in calcium intestinal absorption.25  As 
calcium concentrations return to normal, the release of PTH is suppressed by the influx 
of calcium and activated vitamin D.  The initial rise in PTH will provoke osteoblastic 
activity and bone deposition, utilizing the newly available calcium to increase bone 
mineral density (BMD).24   
Like vitamin D and PTH, estrogen and osteocalcin (OC) also connect the divide 
between bone and metabolism.  Bone resorption increases with marginal downturns in 
estrogen production.21  As an endocrine organ and producer of sex steroids, adipose 
tissue contributes to total estrogen levels.  This finding is supported by the results of 
numerous weight loss studies, which report a correlation between BMD loss and 
reduction in circulating estradiol as body fat decreases.21  Osteocalcin is derived from 
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osteoblasts, which synthesize and secrete the protein into the bone extracellular 
matrix.9,19  Although originating in bone, current evidence suggests OC targets distant 
tissues, adding to the mounting evidence implicating the skeletal system as endocrine 
organ.  Experimental results indicate the influence of OC on glucose homeostasis, 
possibly signaling for insulin secretion of pancreatic β-cells and stimulating receptors for 
glucose uptake in adipose tissue.9 
Adequate intake of calcium intrinsically preserves bone health as an essential 
element of structure.  In addition, calcium influences BMD indirectly through the 
negative feedback loop with PTH, thus inhibiting disproportional bone resorption.1  
Recently, the role of Mg in bone health and metabolism is receiving attention, yet there 
is still much to elucidate.1 
The endocrine functions of the active form of vitamin D, 1α,25-dihydroxyvitamin 
D (1α,25-(OH)2D), are categorized by its actions in calcium homeostasis and its 
regulatory actions in many physiological sites, such as bone marrow, the immune 
system, the intestine, skeletal muscle, and adipose tissue.1  Like a hormone, vitamin D 
interacts with nuclear receptors to enhance or inhibit gene expression, including the 
transcription of proteins involved in energy metabolism and calcium absorption.  With 
many functions, Mg is a critical component in hundreds of biological processes.  As an 
intracellular divalent cation, ionized Mg (iMg2+) functions as a major cofactor for 
enzymes involved in the physiological pathways of lipid and carbohydrate 
metabolism.6,31,32  With many functions, Mg is a critical component in hundreds of 
biological processes. Its actions in the second-messenger systems of cAMP and 
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phospholipase C, and its role as an intracellular calcium antagonist, are particularly 
relevant to its metabolic influence and relationship with vitamin D and PTH.1,2,37 
Current evidence signifies lower average intakes of calcium, vitamin D, and Mg 
in overweight and obese populations. As a major cofactor for proteins and enzymes 
involved in vitamin D metabolism, Deng et al. tested the hypothesis that serum 25OHD 
levels are influenced by dietary Mg, and risk factors of vitamin D insufficiency are thus 
modified.35  Data drawn from the NHANES cross-sectional study and the NHANES III 
cohort confirmed a significant and independent association between high total (dietary 
and supplemental) Mg intake and reduced risk of vitamin D insufficiency and 
deficiency, which interacted with serum PTH levels.35 
Furthermore, results from epidemiological and observational studies suggest an 
inverse association between dietary calcium intake with abdominal obesity and total 
body fat, while higher calcium intakes from dairy products with concomitant energy 
restriction seems to enhance weight loss compared to caloric restriction alone.37  The low 
calcium intakes often occurring with increased adiposity could perpetuate lipogenesis 
via the PTH/vitamin D axis.  Both hormones increase intracellular calcium 
concentrations in adipocytes, subsequently suppressing lipolysis and activating fatty 
acid synthase activity.37  Data from a minimal number of clinical trials have 
demonstrated poor dietary intake of Mg and low serum iMg2+ levels in overweight and 
obese subjects as compared to normal weight controls.3,8 
An inverse relationship between serum Mg and fasting insulin was also 
reported, indicating a predisposal for T2DM development.50  These results are intriguing 
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since serum Mg, rather than intake, more closely correlated to insulin resistance, 
suggesting a mechanistic relationship over dietary magnesium alone.50  Current data 
also indicate a negative correlation between serum 25OHD levels and BMI, and an 
inverse relationship between serum 25OHD and other measurements of adiposity, such 
as total fat mass and WC.30,45,52-54  Body weight, total fat mass, and percent body fat (PBF) 
are significantly and positively correlated with PTH concentrations, while a significant 
negative correlation exists between PTH and physical activity, 25OHD, and dietary 
calcium intake.53 
 Alterations in bone regulating hormones and nutrients are consistently reported 
in overweight and obese populations.20,35,45,46,53  Whether the changes are mere indicators 
of disease or play a causative role is still being investigated.  As an antagonist of 
intracellular calcium, Mg could help to control heightened fat deposition; however, a 
direct biological influence over fluctuations in body mass and metabolism is yet to be 
established.29,42  The vitamin D endocrine system displays modifications in overweight 
and obese individuals.20,45 
 Low vitamin D, elevated PTH, and low Mg status are each independently 
associated with MetS.2,3,7,8  Understanding the influence of bone regulating hormones 
and nutrients on metabolism may lead to new ways of characterizing the MHO 
phenotype.  With varying degrees of influence, some of the proposed protective factors 
include physical activity level, stress management, subcutaneous versus visceral fat, fat 
deposition, duration of obesity, PBF, age, ethnicity, genetics, diet, and possibly the triad 
of low vitamin D, high PTH, and low Mg status.  The goal of this study is to investigate 
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how metabolic abnormalities in overweight and obese individuals are distinctly 
influenced by bone regulating hormones and nutrients.  Vitamin D, PTH, and Mg are all 
independent risk factors for MetS, while simultaneous alterations in all three could be a 
synergistic risk factor for components of MetS.  In the current study, we propose MHO 
individuals will have normal levels of vitamin D, PTH, and Mg, and MUO individuals 
will have the following triad of metabolic alterations: Low dietary intake and blood 
indicators of Mg, low dietary calcium, low serum levels of 25(OH)D, and elevated PTH 
or hyperparathyroidism. 
 
5.2 Subjects and Methods 
5.2.1 Subjects  
Overweight or obese men or women age 18-70 years were recruited from Drexel 
University through use of a standardized research flyer posted across main campus and 
center city campus. Some of these individuals chose to participate in the larger 
randomized control trial while others participated only in baseline measurements. The 
following exclusion criteria was used: individuals with diabetes mellitus, cancer or 
cancer therapy in the past year, kidney disease or kidney stones in the past year, 
immune disease or steroid drug use, unmanaged thyroid disease, heart or stroke in the 
past year, arthritis taking prednisone, liver disease, undergoing hormone replacement 
therapy, on osteoporosis medication, taking magnesium supplements, taking diuretics, 
and/or taking vitamin D supplementation. Premenopausal women were included while 
post-menopausal women and women who are pregnant or planning to become 
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pregnant were excluded. The study was approved by the Drexel University Institutional 
Review Board and all participants signed an informed consent form. 
 
5.2.2 Methods 
 Medical history was collected along with a magnesium food frequency 
questionnaire (Mg FFQ), currently being validated by an ad hoc group of Drexel 
University undergraduate nutrition students. Height was measured with a stadiometer 
and weight with a balance beam scale (Seca 700 Physician's Balance Beam Scale, Chino, 
CA, USA) to the nearest 0.05kg. Body fat, trunk fat and  lean mass was assessed using 
dual energy x-ray absorptiometry (Lunar iDXA, enCORE Software Version 15, GE 
Healthcare, United Kingdom). Blood pressure will be obtained after the participants 
rests for a minimum of 5 minutes before the measurement.  The participant’s systolic 
and diastolic blood pressure will be measured using a sphygmomanometer, measuring 
to the nearest 0.5mmHg. 
 
5.3 Serum Analysis 
 Venipuncture was performed for each participant after an overnight fast of at 
least eight hours. Serum was extracted using a centrifuge at 1400 g for 12 minutes then 
stored at -80 ° until further analysis. Concentrations of PTH and 25OHD were analyzed 
by enzyme-linked immunosorbent assay (ELISA) in batch analysis, using both internal 
and external standards. The total coefficient of variance (CV) for 25OHD was 11.6% 
(Immunodiagnostic Systems Inc., Gaithersbug, MD, USA). The intra-assay and inter-
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assay CV for PTH was 7.0% (ALPCO, Salem, NH, USA). Ionized magnesium (iMg2+) was 
measured using a NOVA-8 analyzer (NOVA 8 analyzer, NovaMedical, MA) with ion 
sensitive electrode method within 6 hours of initial venipuncture for each participant. 
Bone metabolism markers, C-terminal telopeptide of type I collagen (CTx) and 
osteocalcin (Immunodiagnostic Systems Inc., Gaithersbug, MD, USA) were analyzed by 
ELISA in batch analysis, using both internal and external standards.. Intra-assay CV was 
3.0% and inter-assay CV was 10.9% for CTx Elisa. The intra-assay CV was 1.3% and the 
inter-assay CV was 5.1% for osteocalcin. Commercial enzyme-linked immunosorbent 
assay Alpco Insulin (Human) ELISA] Kit was used to assess serum insulin levels and the 
hexokinase method for the measurement of fasting glucose levels. Intra-Assay CV: 6.0%; 
Inter-Assay CV: 9.0%. Serum triglycerides were measured using (Sigma-Aldrich® Serum 
Triglyceride Determination Kit).  Intra-Assay CV: 1.5%; Inter-Assay CV: 1.5% 
 
5.4 Statistical Analysis 
Descriptive data was used to separate participants according to the median of 
percent trunk fat (PTF) into two groups.  The cohort median of 19.2% was used to group 
individuals as either MHO (<19.2%) or MUO- (≥19.2%).  The differences in metabolic 
variables, bone regulating hormones and nutrient intake between the two groups (MHO 
and MUO) were analyzed with one-way ANOVA.  Pearson’s correlation coefficients (r) 
were used to assess the strength of relationship between ionized and dietary magnesium 
levels and other variables.  Analyses were conducted using the IBM SPSS Statistics 
package (IBM Corporation, Armonk, NY, USA; version 24.0.0). p values<0.05 are 
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considered significant. p values 0.051-0.1 are considered trends. Data are presented as 
means ± SD. 
 
5.5 Results 
Twenty-seven adults who were considered overweight with a BMI of 25.0-29.9 
kg/m2 or obese with a BMI of ≥30.0 kg/m2, were classified according to the median 
percent trunk fat value (<19.2% for MHO and ≥19.2% for MUO).  The mean age of the 
MHO (29.99 ± 8.57 yr) and MUO (34.26±9.38 yr) did not differ significantly (See table 7).  
There were 2 women and 11 men in the MHO group, and 9 women and 5 men in the 
MUO group.     
 
 
 
Table 7. Demographic Characteristics of Study Participants 
 MHO (13) MUO (14) p 
Age (yrs) 29.99 ± 8.57 34.26 ± 9.38 0.228 
Gender 11M/ 2F 5M/9F  
Abbreviations: MHO, metabolically healthy obese; MUO, metabolically unhealthy obese;  
M, male; F, female.  
Age was not significantly different between groups.  
There were 11 males and 2 females in the MHO group.  The MUO group had 5 males and 9 females. 
p value was assessed using a one-way ANOVA. ** p<0.001, * p<0.050, t p<0.105 
 
 
 
5.5.1 Parameters of body composition 
The parameters of body composition are presented in table 2. As expected, there 
was a significant difference between the percent trunk fat between groups. MHO group 
was 13.28±4.19% and 23.35±3.83% in the MUO group (p < 0.01) (See table 8). There was 
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no significant difference between groups in weight (MHO of 86.78±11.96 kg and MUO of 
92.22±23.05 kg).  Participants in the MUO group had a significantly lower WC (p < 0.04).  
Mean fat mass was significantly lower in the MHO group (p = 0.001) and lean mass was 
significantly higher in the MHO group (p = 0.001).  The MHO group had a mean trunk 
fat of 11.52 ± 4.05 kg compared to a mean trunk fat of 22.00 ± 9.08 kg in the MUO group, 
which was also statistically significant (p = 0.003).   
 
 
 
Table 8. Body Composition Parameters in Study Population 
 MHO (13) MUO (14) p 
Weight (kg) 86.78 ± 11.96 92.22 ± 23.05 0.454 
WC (cm) 88.16 ± 9.66 99.11 ± 14.01 0.038* 
Fat Mass (kg) 21.20 ± 6.62 41.57 ±17.42 0.001** 
Lean Mass (kg) 134.31 ± 21.25 101.67 ± 22.12 0.001** 
% Body Fat 25.59 ± 7.07 44.78 ± 7.78 0.000** 
Trunk Fat (kg) 11.52 ± 4.05 22.00 ± 9.08 0.003* 
% Trunk Fat  13.28 ± 4.19 23.35 ± 3.83 0.000** 
Abbreviations: MHO, metabolically healthy obese; MUO, metabolically unhealthy obese; WC, waist circumference. 
There was not a significant difference in weight between groups.   
Average WC, fat mass, lean mass, % body fat, and trunk fat were all significantly higher (p < 0.001) in the MUO group 
compared to the MHO group. 
p value was assessed using a one- way ANOVA. ** p<0.001, * p<0.050, t p<0.105 
 
 
 
5.5.2 Metabolic variables in the 2 groups 
The metabolic variables that were assessed in this study is presented in table 9. In 
the MHO group, serum insulin concentrations were significantly lower (p < 0.04) than 
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the MUO group.  Systolic BP did not differ between groups (See table 9), yet diastolic BP 
tended (p < 0.07) to be lower in the MHO group.  Triglyceride and CRP levels did not 
differ between groups.   
 
 
 
Table 9. Metabolic Variables in our Study Population 
 MHO (14) MUO (13) p 
Insulin (pmol/L) 70.19 ± 49.41 157.28 ± 131.66 0.034* 
Glucose (mg/dL) 113.09 ± 11.63 113.31 ± 19.51 0.973 
Systolic (mmHg) 114.80 ± 3.29 113.46 ± 6.31 0.550 
Diastolic (mmHg) 68.40 ± 4.20 72.92  ± 6.25 0.062t 
TGL (mmol/L) 4.77 ± 3.15 6.82 ± 4.70 0.200 
CRP (ng/mL) 102.50 ± 10.56 102.27 ± 8.34 0.951 
Abbreviations: MHO, metabolically healthy obese; MUO, metabolically unhealthy obese; TGL, triglycerides; CRP, C-
reactive protein. 
Insulin was significantly higher (p = 0.034) in the MUO group. 
There was a trend toward higher (p = 0.062) diastolic blood pressure in the MUO group. 
p value was assessed using a one-way ANOVA. ** p<0.001, * p<0.050, t p<0.105 
 
 
 
5.5.3 Dietary intakes in the 2 groups 
The nutrient intake in the 2 groups is presented in table 10. Magnesium intake 
was higher in the MHO group (270.39 ± 181.71 mg/day) than the MUO-PBF group 
(195.38 ± 88.94 mg/day), but this was not significant at the 0.05 level (p = 0.180).  When 
measured using the 24-hour dietary recall, neither the mean intake of calcium and 
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protein differed between groups (See table 10).  However, intakes of vitamin D tended to 
be higher in the MHO than the MUO group (p = 0.134).  
 
Table 10. Dietary Intakes in the Study Population 
 MHO (13) MUO (14) p 
Mg Intake (mg) 270.39 ± 181.71 195.38 ± 88.94 0.180 
Ca Intake (mg) 858.68 ± 485.22 766.07 ± 384.84 0.631 
Protein Intake (g) 110.90 ± 49.48 88.87 ± 30.07 0.233 
Total Fat Intake (g) 84.08 ± 44.51 79.42 ± 33.91 0.789 
Vitamin D intake (µg) 5.35 ± 7.62 1.42 ± 2.37 0.134 
Abbreviations: MHO, metabolically healthy obese; MUO, metabolically unhealthy obese;  
Mg, magnesium; Ca, calcium. 
There were no significant differences in dietary intake between the study groups. 
p value was assessed using a one-way ANOVA. ** p<0.001, * p<0.05, t p<0.105 
 
 
 
5.5.4 Bone regulating hormones and nutrients 
As expected, serum 25OHD concentrations were lower in the MUO group (25.61 
± 6.94 ng/mL) compared to MHO (26.71 ± 6.21), however this was not statistically 
significant (See table 11).  There was a significant difference (p < 0.04) in iMg2+ 
concentrations in the MHO group (0.565 ± 0.41 mmol/L) than in the MUO group (0.525 ± 
0.050 mmol/L).  Furthermore, serum PTH levels were significantly higher (p < 0.02) in 
the MUO group (61.77 ± 25.92 pg/mL) than the MHO group (40.19 ± 11.49 pg/mL). 
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Table 11. Bone Regulating Hormones and Nutrients 
 MHO (13) MUO (14) p 
25OHD (ng/mL) 26.71 ± 6.21 25.61 ± 6.94 0.669 
PTH (pg/mL) 40.19 ± 11.49 61.77 ± 25.92 0.013* 
iMg2+ (mmol/L) 0.565 ± 0.41 0.525 ± 0.050 0.032* 
Abbreviations: MHO, metabolically healthy obese; MUO, metabolically unhealthy obese;  
25OHD, 25-hydroxyvitamin D; PTH, parathyroid hormone; iMg2+, ionized magnesium. 
Serum PTH concentrations were significantly higher (p = 0.013) in the MUO group.   
Serum iMg2+ concentrations were significantly higher (p = 0.032) in the MUO group. 
p value was assessed using a one-way ANOVA. ** p<0.001, * p<0.05, t p<0.105 
 
 
 
5.5.5 Markers of Bone Turnover 
 Serum osteocalcin concentrations and serum CTx concentrations tended to be 
higher in the MHO compared to the MUO group (See table 12). The mean values of OC 
in the MHO were 10.13 ± 3.74 ng/mL and MUO was 7.59 ± 4.04 ng/mL (p = 0.103).  Mean 
CTx levels tended to be higher (p < 0.08) in the MHO group (0.509 ± 0.257 ng/mL) than 
the MUO group (0.332 ± 0.235 ng/mL). 
 
 
 
Table 12. Markers of Bone Turnover 
 MHO (13) MUO (14) p 
Osteocalcin (ng/mL) 10.13 ± 3.74 7.59 ± 4.04 0.103t 
CTx (ng/mL) 0.509 ± 0.257 0.332 ± 0.235 0.073t 
Abbreviations: MHO, metabolically healthy obese; MUO, metabolically unhealthy obese;  
CTx, C-terminal telopeptide of type 1 collagen. 
A trend of higher osteocalcin (p = 0.103) was found in the MHO group. 
A trend of higher CTx (p = 0.073) was found in the MHO group. 
p value was assessed using a one-way ANOVA. ** p<0.001, * p<0.050, t p<0.105 
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5.5.6 Relationship between hormones, Mg status and Body Composition  
Pearson correlation analysis reveals a negative relationship between Mg intake 
(FFQ) and percent body fat (p < 0.03), as well as total fat mass (p < 0.06).  Osteocalcin was 
negatively associated with % body fat (p < 0.05) and there was a negative correlation 
between insulin and serum 25OHD concentrations (p < 0.02).   
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Table 13. The Relationship Between Magnesium Status, Nutrient Intakes, and Metabolic 
Variables 
  Ionized Mg Dietary Mg 
Intake 
Dietary Ca 
Intake 
Vitamin D 
Intake 
Age  r 
p 
0.332 
0.091t 
-0.269 
0.174 
-0.570 
0.006** 
-0.426 
0.048* 
BMI r 
p 
-0.29 
0.142 
-0.073 
0.716 
0.021 
0.927 
-0.104 
0.645 
% Body Fat r 
p 
-0.158 
0.440 
-0.335 
0.095t 
-0.234 
0.308 
-0.116 
0.616 
Body Fat r 
p 
-0.213 
0.296 
-0.232 
0.253 
-0.043 
0.852 
-0.035 
0.879 
Trunk Fat r 
p 
-0.210 
0.304 
-0.242 
0.234 
-0.076 
0.743 
-0.068 
0.768 
% Trunk Fat r 
p 
-0.262 
0.196 
0.166 
0.418 
0.209 
0.363 
-0.021 
0.929 
Insulin r 
p 
-0.185 
0.356 
-0.003 
0.986 
0.002 
0.993 
-0.188 
0.601 
Glucose r 
p 
-0.193 
0.336 
0.144 
0.474 
-0.127 
0.573 
-0.073 
0.748 
Systolic BP r 
p 
0.225 
0.303 
0.252 
0.246 
0.102 
0.678 
0.185 
0.447 
Diastolic BP r 
p 
-0.492 
0.017* 
0.043 
0.845 
-0.07 
0.760 
-0.031 
0.900 
TGL r 
p 
-0.067 
0.741 
-0.182 
0.364 
0.127 
0.572 
-0.093 
0.680 
Abbreviations: Mg, magnesium; Ca, calcium; BMI, body mass index; BP, blood pressure; TGL, triglycerides. 
There was a significant negative correlation (p = 0.006) between age and dietary calcium 
A significant negative correlation (p = 0.048) was found between age and vitamin D intake.   
Results demonstrated a trend of higher (p= 0.091) ionized Mg with greater age.   
A positive trend existed between % body fat and dietary Mg intake (p = 0.095) 
A significant negative correlation (p = 0.017) was found between diastolic BP and ionized Mg. 
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Pearson’s moment correlation (r) and corresponding p value is presented. ** p is significant at the 0.01 level (2-tailed). * p 
is significant at the 0.05 level (2-tailed). t p for trend at the 0.051-0.105 level (2-tailed). 
 
 
 
Table 14. Relationship Between Bone Regulating Hormones and Markers and Metabolic 
Variables 
  PTH 
 
25OHD Osteocalcin CTx 
Age  r 
p 
0.526 
0.006** 
-0.047 
0.817 
0.537 
0.004** 
-0.524 
0.005** 
BMI r 
p 
0.208 
0.308 
-0.189 
0.345 
-0.065 
0.748 
-0.125 
0.533 
% Body fat r 
p 
0.591 
0.002** 
-0.197 
0.336 
-0.398 
0.044* 
-0.458 
0.019* 
Insulin r 
p 
0.095 
0.646 
-0.447 
0.019* 
-0.052 
0.796 
-0.227 
0.225 
Glucose r 
p 
0.181 
0.377 
-0.259 
0.193 
-0.068 
0.738 
-0.125 
0.535 
Systolic BP r 
p 
-0.331 
0.132 
0.284 
0.188 
0.194 
0.375 
0.177 
0.419 
Diastolic BP r 
p 
-0.057 
0.802 
-0.054 
0.808 
-0.185 
0.398 
0.043 
0.847 
TGL r 
p 
0.154 
0.453 
-0.05 
0.805 
-0.086 
0.669 
0.221 
0.269 
Ionized Mg r 
p 
0.163 
0.426 
0.096 
0.634 
-0.03 
0.881 
-0.218 
0.274 
Abbreviations: PTH, parathyroid hormone; 25OHD, 25-hydroxyvitamin D; CTx, C-terminal telopeptide of type I collagen; 
BMI, body mass index; BP, blood pressure; TGL, triglycerides; Mg, magnesium. 
Age was significantly and positively correlated (p = 0.006) with serum PTH. 
Age was significantly and positively correlated (p = 0.004) with serum osteocalcin concentrations. 
A significant negative relationship (p = 0.005) existed between age and CTx.   
There was a significant positive correlation (p = 0.002) between % body fat and PTH. 
A negative correlation (p < 0.050) was found between % body fat and markers of bone formation, osteocalcin and CTx.   
A significant negative relationship (p = 0.019) was found between insulin and serum 25OHD. 
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Pearson’s moment correlation (r) and corresponding p-value is presented. ** p is significant at the 0.01 level (2-tailed). * p 
is significant at the 0.05 level (2-tailed). t p or trend at the 0.051-0.105 level (2-tailed). 
 
 
 
Figure 3. Relationship Between Serum Parathyroid Hormone and Percent Body Fat 
 
Abbreviations: PTH, parathyroid hormone. 
A positive linear relationship  (p = 0.002; r = 0.591) was found between serum PTH concentrations and % body fat. 
Pearson’s moment correlation (r) and corresponding p-value is presented. ** p is significant at the 0.01 level (2-tailed). * p 
is significant at the 0.05 level (2-tailed). t p or trend at the 0.051-0.105 level (2-tailed). 
 
 
 
5.6 Discussion 
The aim of this study was to determine how bone regulating hormones and 
nutrients characterize the MHO phenotype, and whether a relationship exists between 
Mg status, bone regulating hormones, and adiposity. Our results show that individuals 
in the MHO group had greater lean mass, and lower fat mass, percent body fat, trunk 
fat, and percent trunk fat compared to those in the MUO group, yet weight did not 
differ between groups.  Data from the present study reveal significantly higher iMg2+ 
and a statistical trend of higher dietary Mg intake in the MHO group.  In addition, there 
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was a negative correlation between % body fat and dietary Mg intake.  These data are 
consistent with findings of poor dietary intake of Mg and low serum Mg levels in 
overweight and obese participants compared to normal weight controls.3,8  Higher intake 
of Mg-rich foods implies a better diet for weight maintenance, while presuming the diet 
adhered to by many obese individuals would be lacking good sources of the mineral.  
Another interesting questions is whether Mg has a mechanistic influence on weight. As 
an antagonist of intracellular calcium, Mg could help to control heightened fat 
deposition; however, a direct biological influence over fluctuations in body mass and 
metabolism has yet to be established.29,42 
 Overall, the MUO group had greater total adiposity and stronger indicators of 
visceral fat than those in the MHO group, predictive of metabolic abnormalities.  Our 
data suggest the MHO individual may have lower blood pressure and higher insulin 
sensitivity, yet markers of dyslipidemia and systemic inflammation did not differ.  There 
was a significant negative correlation between ionized Mg and diastolic BP, and no 
relationship with systolic BP.  In cross-sectional and clinical trials with Mg 
supplementation, Mg status has been inversely associated with both SBP and DBP 
values.33,69  Extracellular Mg may have a direct influence on BP by promoting vascular 
relaxation, or vasodilation, as a calcium-channel blocker, while low intracellular Mg in 
erythrocytes seems to impact vascular structure (e.g. arterial stiffness and thickening), 
leading to endothelial dysfunction.33,69   
 Although there was no direct relationship between Mg status and glycemic 
indices, the MUO group had a significantly higher mean fasting insulin concentration, 
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and lower dietary and ionized Mg.  Results from other investigations support the 
influence of Mg on insulin sensitivity.  Huerta et al. reported an inverse relationship 
between serum Mg and fasting insulin.50  Serum Mg, rather than intake, more closely 
correlated to insulin resistance, suggesting a mechanistic relationship over dietary 
magnesium alone.50  In a cross-sectional cohort study of an obese population, 
participants with MetS and T2DM had significantly lower serum Mg concentrations 
compared to participants without T2DM, which was supported by a significant 
correlation between Mg and parameters of insulin resistance.6   
Our study results did not suggest a relationship between Mg and certain lipid 
markers; however previous research is contradictive.  Low ionized and serum Mg 
negatively correlated with triglycerides, total cholesterol, and LDL-C, and positively 
correlated with HDL-C in populations with T2DM and MetS.  This same atherogenic 
lipid profile has been positively correlated to serum calcium, while an inverse 
relationship exists between dietary calcium and Mg in obese individuals with 
dyslipidemia.36,37  In a cross-sectional analysis of 11,686 women, Song et al. reported a 
significant inverse association between a Mg intake of 326 mg/day, slightly above the 
RDA, and plasma concentrations of CRP.2  The antioxidant effect of Mg was more 
evident in participants within the higher BMI range.  Lowered fasting insulin levels 
were detected in subjects with increased Mg intake, which could be a secondary benefit 
to the control of oxidative stress.2 
The central hypothesis in this study was that bone regulating hormones and 
nutrients will characterize the MHO phenotype.  In the present study, serum PTH 
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concentrations were significantly higher in the MUO group, and showed a significant 
positive relationship with % body fat.  Previous evidence suggests PTH to be a strong 
predictor of fat mass and other measurements of adiposity, and not body weight alone.53  
Sukumar et al. reported high PTH levels in heavier compared to leaner women, and 
both serum 25OHD and PTH were significantly influenced by BMI.23,53  In the present 
study, we identified a significant positive correlation between PTH and % body fat, 
rather than BMI.  Chronic elevation of PTH secretion causes an influx of calcium into the 
blood from bone resorption and reabsorption in the renal tubules.41,42  As more 
circulating calcium is taken up by adipocytes, the higher intracellular concentration of 
the mineral can promote increased lipid storage and perpetuate the accumulation of fat 
tissue, while contributing to the vascular calcification contributing to CVD 
development.6   
The mean serum 25OHD value did not differ in the MHO participants. Although 
higher, this difference was not statistically significant.  Ample evidence supports an 
inverse relationship between serum 25OHD and measurements of adiposity, such as 
total fat mass and WC.30,45,52,53,54  Our research results did not reveal a relationship 
between 25OHD or PTH and the presence of metabolic abnormalities with the exception 
of significant negative correlation between serum 25OHD and insulin.  The latter is 
consistent with reports of higher insulin sensitivity in obese participants with greater 
lean mass and higher levels of vitamin D.81  The lack of other associations between these 
bone regulating hormones and components of MetS contradicts findings of low vitamin 
D, elevated PTH, and low Mg status to each be independently correlated with MetS.2,3,7,8  
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Results from a study conducted by Hjelmesaeth et al. decisively revealed serum PTH 
levels as an independent predictor of MetS with or without diabetes, while suggesting a 
mechanistic effect of PTH on BP.6  Elevated WC, fasting blood glucose, and serum 
triglycerides are also associated with chronically low levels of serum 25OHD.62  None of 
our participants fell in deficiency range and only a few were insufficient, which may be 
why we did not attain similar results.  Osteocalcin also tended to be higher in the MHO 
compared to the MUO group. Recently, osteocalcin, a bone formation marker has been 
implicated in regulation of energy metabolism and promoting insulin sensitivity. A 
higher osteocalcin and lower insulin in the MHO group supports better glycemic control 
in this group than the MUO group. 
Calcium and protein intake were all higher in the MHO group, yet these findings 
were not significant.  The MHO group also had a higher fat intake, insinuating the male 
dominant group may have been consuming more food overall rather than foods rich in 
these nutrients.  In previous research, higher dietary intakes of calcium have 
demonstrated a protective affect against the components of MetS, including insulin 
resistance, dyslipidemia, HTN, and chronic inflammation.37  The mean calcium intake 
for both groups was below the RDA of 1000 mg/day.  This finding is consistent with 
data from epidemiological and observational studies indicating an inverse association 
between dietary calcium intake and both abdominal obesity and total body fat, while 
higher calcium intakes from dairy products with concomitant energy restriction seems 
to enhance weight loss compared to caloric restriction alone.37  The low calcium intakes 
often occurring with increased adiposity could perpetuate lipogenesis via the 
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PTH/vitamin D axis.  Both hormones increase intracellular calcium concentrations in 
adipocytes, subsequently suppressing lipolysis and activating fatty acid synthase 
activity.37 
In addition, high intracellular calcium inhibits the dephosphorylation of GLUT4, 
diminishing insulin response in adipose tissue.37,46  Without adequate Mg levels or 
dietary calcium to help control intracellular calcium concentrations, translocation of 
GLUT4 is further reduced and metabolic efficiency is compromised.46  The detrimental 
affect of high intracellular calcium may be why the combination of low Mg status, low 
dietary calcium, and high PTH often coincide with insulin resistance.  The MUO group 
did fit this description and had significantly higher fasting insulin, suggesting a 
relationship exists.  Low vitamin D is also associated with reduced expression of insulin 
receptors and impaired dephosphorylation of GLUT4 subsequent to insulin 
binding.45,49,52,67  There was a statistical trend toward higher intake of vitamin D in the 
MHO group, although this was not reflected in their serum 25OHD concentrations.  
There were no correlations between vitamin D intake and metabolic abnormalities.  
Dietary sources of vitamin D are limited to fatty fish, fish oil, organ meats, egg yolks, 
and certain mushroom species, and fish intake is beneficial for blood sugar control.1 
We correctly predicted the MHO group would have lower serum PTH and 
higher iMg2+ concentrations.  However, there was no difference in serum 25OHD 
concentrations between groups, perhaps due to the seasonal affect on vitamin D status.  
There was a significant difference in PTH and Mg status between groups, yet this 
statistical finding may or may not translate to clinical significance.  The mean serum 
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iMg2+ concentrations in both groups was lower than what is considered normal (≥0.60 
mmol/L), which is consistent with evidence of low blood indicators of magnesium in 
overweight and obese populations (Deng).  More research is needed to determine 
whether the difference of Mg status between the MHO and MUO groups is enough to 
offer health benefits.  The diagnostic values of normal PTH is 12-55 pg/mL, so the MHO 
group fell within the recommended range (40.19 ± 11.49 pg/mL) while the MUO group 
showed clinically high PTH concentrations (61.77 ± 25.92 pg/mL).  In summary, the 
health benefits of the MHO phenotype, according to our definition, included lower 
diastolic blood pressure, better Mg status, and normal concentrations of serum PTH (See 
table 15).   
 
 
Table 15. Summary of Findings 
 
Parameter 
 
MHO 
 
Blood Pressure 
 
Lower Diastolic Blood Pressure 
 
Fasting Blood Glucose 
 
No Difference 
 
Triglycerides 
 
No Difference 
 
C-reactive Protein 
 
No Difference 
 
Magnesium Status 
Significantly Higher Serum iMg2+ 
Slightly Higher Intake 
 
Vitamin D 
No Difference 
Slightly Higher Intake 
 
Parathyroid Hormone 
 
Significantly Lower 
 
Dietary Calcium 
 
No Difference 
Abbreviations: iMg2+, ionized magnesium. 
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5.6.1 Strengths and limitations 
The characterization of the MHO phenotype has been highly variable in the 
literature and to our knowledge very few studies have examined bone regulating 
hormones and markers in relationship to this phenotype. A comprehensive examination 
of the important bone regulating hormones, turnover markers, metabolic indices and 
body composition measures is a major strength in our study. A small sample size, 
homogeneity in our study population is some limitations and it is possible that some of 
the trends observed in the study may be statistically significant with a larger sample 
size. Future studies should consider examining these bone regulating hormones and 
nutrients in characterizing the MHO phenotype. Importantly alterations in these 
hormones and nutrients can be a potential target for intervention for prevention of 
metabolic abnormalities.  
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APPENDIX A: Informed Consent 
	
Drexel University  
Consent to Take Part 
In a Research Study 
1. Title of research study : Magnesium Supplementation in Obesity: A 
Novel Therapy for Vitamin D Treatment Resistance 
2. Researcher: Deeptha Sukumar, PhD 
3. Why you are being invited to take part in a research study 
We invite you to take part in a research study because you meet the study criteria of 
being within ages 18-70 years, have a serum vitamin D level in the insufficient or 
deficient range and have a Body Mass Index greater than 25 kg/m2  
4. What you should know about a research study 
• Someone will explain this research study to you. 
• Whether or not you take part is up to you. 
• You can choose not to take part. 
• You can agree to take part now and change your mind later. 
• If you decide to not be a part of this research no one will hold it against 
you. 
• Feel free to ask all the questions you want before you decide. 
5. Who can you talk to about this research study? 
If you have questions, concerns, or complaints, or think the research has hurt you, talk to 
the research team at [215 762 3698 or deeptha.sukumar@drexel.edu] 
This research has been reviewed and approved by an Institutional Review Board (IRB). 
An IRB reviews research projects so that steps are taken to protect the rights and welfare 
of human subjects taking part in research.  You may talk to them at (215) 255-7857 or 
email HRPP@drexel.edu for any of the following: 
• Your questions, concerns, or complaints are not being answered by the 
research team. 
• You cannot reach the research team. 
• You want to talk to someone besides the research team. 
• You have questions about your rights as a research subject. 
• You want to get information or provide input about this research. 
6. Why are we doing this research? 
Raising vitamin D levels has been associated with numerous health benefits in the 
overweight/obese population. This includes but is not limited to improvements in blood 
pressure, cholesterol levels and glucose levels. The problem with giving vitamin D 
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supplementation to the overweight/obese adult is that they need 2-3 times more doses of 
vitamin D supplements to raise their blood levels of vitamin D compared to normal 
weight adults.  
This study will address whether using Magnesium together with normal doses of 
vitamin D supplementation, will improve vitamin D blood levels in overweight-obese 
participants.  
7. How long will the research last? 
We expect that you will be in this research study for 4 months  
8. How many people will be studied? 
We expect about 40 people here will be in this research study out of 40 people in the 
entire study nationally  
9. What happens if I say yes, I want to be in this research? 
If you are willing to participate in this study, you will be required to come to the 
research facility at 3rd floor- Room 317, 1601 Cherry street, Philadelphia, PA for 
6 visits.  
• During these visits you will interact with the research personnel 
• These visits are called 
o Screening visit 
o Baseline visit 
o Wk-6 visit 
o Wk-12 visit 
• At each of the following visits, you can expect to undergo the listed study 
procedures 
• Screening visit 
o This visit will last for about 45 minutes 
o Blood draw-  Three 5 ml tubes of blood will be collected via 
venipuncture 
o Spot urine sample collection 
o Measurement of height, weight, blood pressure, waist 
circumference 
o Completion of study questionnaires 
• You will be contacted by phone or email to inform you whether you are 
eligible for the study. 
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• Baseline visits 
o 2 visits in 2 consecutive weeks 
 
o This visit will last for about 30 minutes.  
o Blood draw- Three 5 ml tubes of blood will be collected  via 
venipuncture 
o Spot urine sample collection 
o Measurement of height, weight, blood pressure, waist 
circumference 
o Completion of study questionnaires 
o Distribution of study pills- Vitamin D, Vitamin +Mg, or higher 
dose of vitamin D supplementation 
o A dual-energy x-ray absorptiometry (DXA) scan will be conducted 
on the 2nd floor of the 3 Parkway building. The scanning device 
detects bone, fat, and muscle in the body. All female participants 
will be required to complete a urine pregnancy test before 
undergoing DXA scan. A positive test will result in exclusion from 
the DXA scan. You should not wear clothes with metal parts 
during this test. You will lie flat on the bed of the scanner. The scan 
will take approximately 30 minutes (in addition to one of the 30 
minute visit). Your scan will be conducted by trained personnel, 
and a certified radiation technologist will be available to evaluate 
the results. 
• Wk-3, 6 and wk-12 visits 
o These visits will last for about 30 minutes 
o Blood draw- Three 5 ml tubes of blood will be collected via 
venipuncture 
o Spot urine sample collection 
o Measurement of height, weight, blood pressure, waist 
circumference 
o Completion of study questionnaires 
 
Apart from the above mentioned procedures, you will be expected to consume 
the study supplements daily at home with meals. In addition you will also be 
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required to complete a food diary for 3 days every week during the 12- week 
study which will take you about 10 minutes/day for completing the food diary. 
There are 3 groups in this study.  
Vitamin D group: 1000 IU Vit D 
Vitamin D + Mg group: 1000 IU Vit D+ 360 mg Magnesium  
High Dose Vitamin D group: 2500 IU Vit D  
You will be required to take four pills every day. Depending on your treatment 
allocation you will receive vitamin D, magnesium, placebo, or a combination of the two. 
The treatment you get will be chosen by chance, like flipping a coin. Neither you nor the 
study doctor will choose what treatment you get. You will have an one in three chance 
of being given each treatment. Neither you nor the study doctor will know which 
treatment you are getting.  
10. What are my responsibilities if I take part in this research? 
If you take part in this research, it is very important that you 
Follow your physician’s or researcher’s instructions. 
• Tell your study physician or researcher right away if you have a complication or 
injury. 
• Limit your sun exposure between hours of 10 A.M – 3 P.M 
• Use a sunscreen of SPF 50 at all times. 
• Do not use any other dietary supplements during the period of this study. 
• Take the study pills according to the instructions of the researchers 
11. What happens if I do not want to be in this research? 
You may decide not to take part in the research and it will not be held against you. 
12. What happens if I say yes, but I change my mind later? 
You agree to take part in the research now and stop at any time it will not be held 
against you. 
If you stop being in the research, already collected data may not be removed from the 
study database. You will be asked whether the researcher can collect data from your 
routine medical care. If you agree, this data will be handled the same as research data.  
13. Is there any way being in this study could be bad for me? 
There should be no discomforts in this study other than the blood drawing 
which can result in a temporary slight discoloration in the skin surrounding it. 
Some side effects of taking too much vitamin D include weakness, fatigue, 
sleepiness, headache, loss of appetite, dry mouth, metallic taste, nausea, 
vomiting. Common side effects from taking magnesium supplements include 
upset stomach and diarrhea. However the doses that are prescribed in this study 
are much lower than the upper limit for these nutrients set by the Institute of 
Medicine and should not pose any adverse effects. The DXA scan will expose 
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you to very small amounts of radiation. The risks from this exposure, if they exist 
at all are minimal.   
You and your insurance company will be charged for the health care services 
that you would ordinarily be responsible to pay. In some cases, insurance will 
not pay for services ordinarily covered because these services were performed in 
a research study. You should check with your insurance to see what services will 
be covered by your insurance and what you will be responsible to pay. 
14. Do I have to pay for anything while I am on this study? 
There is no cost to you for participating in this study.   
You will not be charged for any tests specifically required for this research study, but 
you or your insurance company will still be billed for tests or procedures that are 
considered “standard of care” and would have been part of your medical treatment even 
if you did not participate in this study. These treatment costs include but are not limited 
to drugs, routine laboratory tests, x-rays, scans, surgeries, routine medical care, and 
physician charges.  Your health insurance company may not pay for these “standard of 
care” charges because you are in a research study.  If your insurance company does not 
pay for costs associated with this research study that are considered “standard of care” 
for your medical treatment, then you will be billed for these costs.  You are responsible 
for paying for any insurance co-pays and any deductibles due under your insurance 
policy, and any charges your insurance company does not pay. 
15. Will being in this study help me any way? 
There are no benefits to you from your taking part in this research. We cannot promise 
any benefits to others from your taking part in this research. However, possible benefits 
to others such as to the researchers include a knowledge of how vitamin D treatment 
resistance can be cured using Magnesium supplementation.  
16. What happens to the information we collect? 
Efforts will be made to limit your personal information, including research study and 
medical records, to people who have a need to review this information. We cannot 
promise complete secrecy. Organizations that may inspect and copy your information 
include the IRB and other representatives of this organization.  
Data or specimens will be retained after the study for future research to examine if 
certain biomarkers such as bone turnover markers respond to vitamin D and 
Magnesium supplementation or to understand how supplementation influences the 
obese /overweight population compared to normal weight populations. Data and 
specimens will be stored in 3711 Market street, Philadelphia, PA and/or at 1601 Cherry 
street, Philadelphia, PA . Access to samples beyond completion of the study is limited to 
only study personnel. 
The monitors, auditors, the IRB, the Food and Drug Administration will be 
granted direct access to your medical records for verification of the research 
procedures and date. By signing this document, you are authorizing this access. 
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We may publish the results of this research. This includes using data from this research 
for student research such as a master’ s thesis. However, we will keep your name and 
other identifying information confidential. 
17. Can I be removed from the research without my OK? 
The person in charge of the research study or the sponsor can remove you from the 
research study without your approval. Possible reasons for removal include, failure to 
follow study protocol, no –show for more than 3 scheduled visits or failure to meet 
continued study criteria due to illness/medications.  
18. What else do I need to know? 
This research study is being done by Drexel University. If you become ill or 
injured during the study, contact Dr. Sukumar at 215-762-3698. We will get you 
medical care. If you need care right away, go to the nearest emergency room or 
call 9-1-1. Inform all medical emergency staff that you are taking part in this 
study 
 
If you agree to take part in this research study, you will be provided with a $30 
gift card. If for some reason, you cannot complete all measurements, we will 
provide you a $15 gift card for your time and effort 
 
Federal law provides additional protections of your personal information that are 
described here. 
1 Individually Identifiable Health Information That Will Be Collected 
The following personal health information about you will be collected and used during 
the research study and may be given out to others:  
• Your name, address, telephone number, date of birth; 
• Personal and family medical history; 
• Information from laboratory tests, blood and urine tests, x-rays, physical 
exams and other tests or procedures described in this consent form. 
• Information learned during telephone calls, surveys, questionnaires and 
office visits done as part of this research study; 
• Information in medical records located in your doctor’s office or at other 
medical facilities you may have received treatment that are provided by 
you to the researchers. 
2 Who Will See and Use Your Health Information within Drexel University  
The researcher and other authorized individuals involved in the research study at 
Drexel University will see your health information during and may give out your health 
information during the research study. These include the researcher and the research 
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staff, the institutional review board and their staff, legal counsel, research office and 
compliance staff, officers of the organization and other people who need to see the 
information in order to conduct the research study or make sure it is being done 
properly. Your health information may be disclosed or transmitted electronically. 
3 Who Else May See and Use your Health Information 
Other persons and organizations outside of Drexel University may see and use your 
health information during this research study. These include:  
• Governmental entities that have the right to see or review your health 
information, such as The Office for Human Research Protections, and the 
Food and Drug Administration 
• Doctors and staff at the hospital where this research study will take place. 
• A data safety monitoring board. 
If your health information is given to someone not required by law to keep it 
confidential, then that information may no longer be protected, and may be used or 
given out without your permission. 
4 Why your health information will be used and given out 
Your information may also be used to meet the reporting requirements of governmental 
agencies. 
5 If you do not want to give authorization to use your health information 
You do not have to give your authorization to use or give out your health information. 
However, if you do not give authorization, you cannot participate in this research study. 
6 How to cancel your authorization 
At any time you may cancel your authorization to allow your health information to be 
used or given out by sending a written notice to Human Research Protection at 1601 
Cherry Street, 3 Parkway Bldg., Mail Stop 10-444, Philadelphia, Pennsylvania, 19102. If 
you leave this research study, no new health information about you will be gathered 
after you leave. However, information gathered before that date may be used or given 
out if it is needed for the research study or any follow-up. 
7 When your authorization ends 
Your authorization to use and give out health information will continue until you 
withdraw or cancel your authorization. 
After the research study is finished, your health information will be maintained in a 
research database. Drexel University shall not re-use or re-disclose the health 
information in this database for other purposes unless you give written authorization to 
do so. However, the Drexel University Institutional Review Board may permit other 
researchers to see and use your health information under adequate privacy safeguards. 
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8 Your right to inspect your medical and research records 
You will not be able to look at your research records while you are taking part in this 
research study. Your personal information will be made available in an emergency if 
doctors need this information to treat you. You can have access to your medical record 
and any research study information when the study is over. However, the researcher 
does not have to release research information to you if it is not part of your medical 
record. Use this paragraph for blinded or other studies where access will be denied. 
 
Your signature documents your permission to take part in this research. 
DO NOT SIGN THIS FORM AFTER THIS 
DATE 
à 12/08/2016 
   
Signature of subject  Date 
 
 
Printed name of subject 
   
Signature of person obtaining consent  Date 
   
Printed name of person obtaining consent  Form Date 
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APPENDIX B: Medical History Form 
	
Drexel University- Medical History Form 
 
 
Please complete the following questions to the best of your ability.  If you are unclear what to 
answer, leave the space blank and we will help with the answer when you are seen at this facility.  
All answers will be kept in strict confidence and treated as information in your research record. 
 
Name: __________________________ Today’s date: ______________________ 
 
Address: ________________________ Date of Birth: ______________________ 
 
 _________________________  Race:  Caucasian__ Asian__  
       African American__ 
       Native American__ Hispanic__ 
 
If you have a preferred contact number, please check  
 
___   Home #:______________________      ____ Cell # _________________________ 
 
___ Work # _________________________ 
 
E-mail: _________________________     
 
Date of Last medical check-up: ______ Height: __________Weight:____________ 
          
Yes  No 
1. Do you have a medical history of diabetes,    ___ 
hypertension or heart disease? 
 
2. Do you smoke?      ___  ___ 
 
 If yes, how much? _________________________________________________ 
 
3. Have you smoked in the past?    ___  ___ 
 
 If yes, when did you quit? ___________________________________________ 
 
4. Do you consume alcohol?     ___  ___ 
  
If yes, how many drinks per week? ____________________________________ 
 
5.   Have you ever been diagnosed with an eating disorder?  (binge-eating, anorexia nervosa, 
laxative abuse? 
 YES______  NO_______ 
 If yes please explain________________________________________________ 
  
_________________________________________________________________ 
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Drexel University- Medical History Form 
 
 
 
7. Have you had any of the following conditions?: 
 Partial or complete paralysis     ___  ___ 
 Hyperthyroidism      ___  ___ 
 Juvenile diabetes      ___  ___ 
 Hypertension       ___  ___ 
 Elevated Cholesterol      ___  ___ 
Kidney Disease      ___  ___ 
 Liver Disease       ___  ___ 
Rheumatoid Arthritis      ___  ___ 
Other Arthritis       ___  ___ 
Alcoholism       ___  ___ 
Part of stomach removed     ___  ___ 
Inflammatory Bowel Disease     ___  ___ 
Peptic Ulcers       ___  ___ 
Malignant Disease/Cancer     ___  ___ 
  
 
8. Have you taken any of the following in the last year? 
 Steroids (prednisone, cortisone, etc)    ___  ___ 
 Thyroid Medication      ___  ___ 
 Anticonvulsants      ___  ___ 
 Diuretics (water pills)      ___  ___ 
 Gluccocorticoids      ___  ___ 
 Anticonvulsants      ___  ___ 
 Blood Thinners      ___  ___ 
 Antacids       ___  ___ 
 Antibiotics       ___  ___ 
 Have you used steroids for more than 1 year?  ___  ___ 
 
9. Do you have any general comments or questions about your past health? _______ 
 
 __________________________________________________________________ 
 
10. Please list all current medications_______________________________________ 
 
 __________________________________________________________________ 
 
11. Please list medical problems___________________________________________ 
 
 __________________________________________________________________ 
 
  
12. Have you recently lost or gained more than 10 lbs? _______  
 
If yes, please explain.________________________________________________ 
    Y                      N 
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APPENDIX C : Magnesium Food Frequency Questionnaire 
MAGNESIUM FOOD FREQUENCY QUESTIONNAIRE 
 
This questionnaire determines your usual eating habits and foods high in magnesium 
 
First: Mark whether your usual serving size (SS) is small (1/2), medium (1), or large (2 times; 2x)   
Second: Record how often you eat each food (daily, weekly or monthly), and write the number in that 
column 
  Your Usual  
Serving Size 
(SS) 
How Often Do You Eat or Drink  
This Food or Beverage? (Fq) 
 
Food Source 
Containing 
Magnesium 
 
 
 
½   
 
1 
 
2x   
# of 
Times 
/  
Day 
# of 
Times 
/ 
Week 
# of 
Times /  
Month 
 
TOTAL 
  Magnesium 
content (mg) 
Fq* 
SS 
(Fq* 
SS) / 7 
(Fq*SS) 
/ 30 
 
Lentils, raw 1 cup 45 90 180     
Collards, cooked, 
boiled, drained, without 
salt 
1 cup, 
chopped 
20 40 80     
Kale, raw 1 cup 4 8 16     
Spinach, raw  1 cup 12 24 48     
Spinach, frozen, 
chopped or leaf, cooked, 
boiled, drained, without 
salt 
½ cup 39 78 156     
Nuts, cashew nuts, dry 
roasted, with salt added 
½ cup 89 178 356     
Pecans ½ cup, 
halves 
30 60 120     
Seeds, pumpkin and 
squash seeds, whole, 
roasted, with salt added 
1  cup 84 168 336     
Seeds, sunflower seed 
kernels, toasted, with 
salt added 
1 cup 86.5 173 346     
Beans, black, mature 
seeds, canned, low 
sodium 
1 cup 42 84 168     
Chickpeas (garbanzo 
beans, bengal gram), 
mature seeds, canned, 
solids and liquids 
1 cup 32.5 65 130     
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Salmon, wild, cooked, 
moist heat 
3 oz. 15 30 60     
Mackerel, Atlantic, 
cooked, dry heat 
3 oz. 41 82 164     
Fish, tuna, light, canned 
in water, drained solids 
3 oz. 10 20 40     
Chicken, broiler or 
fryers, breast, skinless, 
boneless, meat only, 
cooked, grilled 
3 oz. 14.5 29 58     
Peanut butter, smooth 
style, with salt 
2 tbsp 27 54 108     
Peanut butter, chunk 
style, with salt 
2 tbsp 25.5 51 102     
Banana, raw 1 small  
(6" to 6-
7/8" long) 
13.5 27 54     
Strawberries, raw 1 cup, 
whole 
9.5 19 38     
Blackberries, raw 1 cup 14.5 29 58     
Raisins, seedless 1 small 
box (1.5 
oz) 
7 14 28     
Quinoa, cooked 1 cup 59 118 236     
Bread, whole-wheat, 
commercially prepared 
1 slice 
(32g) 
12 24 48     
Bread, white, 
commercially prepared 
(includes soft bread 
crumbs) 
1 slice 
(25g) 
3 6 12     
Rice, brown, long-grain, 
cooked 
1 cup 42 84 168     
Cereals, oats, regular 
and quick, not fortified, 
dry 
1 cup 56 112 224     
Cereals, QUAKER, 
QUAKER MultiGrain 
Oatmeal, dry 
1 cup 46 92 184     
Yogurt, fruit variety, 
nonfat 
1 
container 
(6 oz) 
13 26 52     
Milk, whole, 3.25% 
milkfat, with added 
vitamin D 
8 oz. 12 24 48     
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Coffee, brewed from 
grounds, prepared with 
tap water 
8 oz. 3.5 7 14     
Orange juice drink 8 oz. 3.5 7 14     
Candies, SPECIAL 
DARK Chocolate Bar 
1 bar (73g) 11.5 23 46     
Avocado, raw, all 
commercial varieties  
1 cup, 
cubes 
22 44 88     
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
		
	
101	
APPENDIX D: 24-Hour Dietary Recall 
 
 
